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Chapter 1
Introduction and outline of the thesis
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Introduction
The incidence of breast cancer is increasing worldwide. The yearly incidence in
the Netherlands is rising to 127 new breast cancer patients per 100.000 women,
or 11.700 patients in 2002. At the moment, one in nine women in the Netherlands
has a lifetime risk for developing breast cancer. The mortality rate amounts to
3500 patients and decreases yearly with 1%. In recent years, the 5-year survival
rate has improved to 80% for patients of all ages1,2.
In breast cancer patients, the histologic status of the axillary lymph nodes is the
most important prognostic factor3. To guarantee appropriate staging and indicate
the need for adjuvant treatment, an axillary lymph node dissection (ALND) has
long been the golden standard4-6. Other reasons to perform an ALND were
enhanced regional control and survival benefit7-12. However, an ALND often
implicates morbidity in terms of lymphedema, seroma formation, reduced shoul-
der motility and chronic pain13-16. This might lead to a reduction in quality of life
in exchange for the advantages.
In the seventies, the sentinel lymph node concept was developed by Cabañas in
patients with penile cancer17. The sentinel lymph node (SLN) is the first lymph
node to receive lymph drainage from a primary tumour and is therefore the first
node to contain metastatic disease if lymphatic metastasis occurs. Cabañas
localised the SLN by anatomical landmarks. Morton transferred this SLN concept
to melanoma patients for staging in 199218. He localised the SLN by visualisation
of the lymphatic duct leading to the SLN with blue dye. One year later a radioac-
tive tracer and use of the gamma probe was added to facilitate pre- and intraop-
erative identification of the SLN19. The same year the first publication appeared
on application of the SLN concept in breast cancer patients20.
As in melanoma, many validation studies were performed in breast cancer
patients. During these studies, all SLN biopsies were routinely followed by a com-
pletion ALND. The histological status of the SLN appeared to be predictive for the
remaining axillary lymph nodes in patients with clinical T1-2N0 breast cancer. It
is therefore a reliable alternative to the traditional ALND and an accurate staging
procedure in breast cancer patients16,21-23. If metastatic disease is found in the
SLN, a completion ALND is recommended to optimise regional control, complete
staging and enhance survival4,11. When the SLN is tumour free, it was hypothe-
sised patients can be spared an ALND and its concomitant morbidity.
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The procedure: the triple technique of the sentinel lymph node biopsy (SLNB).
The SLN mapping was performed using 60 MBq of technetium-99m nanocolloid
as a radioactive tracer and 1 cc blue dye (Bleu patente V; Guerbet, Aulnay-sous-
Bois, France) for lymphatic mapping. Both were injected into breast parenchymal
tissue surrounding the tumour or biopsy cavity. The tracer will search its way
through draining lymph vessels to the first receiving lymph node. This SLN can
be identified and harvested by use of the following triple technique: the lym-
phoscintigraphy with skin marking of the presumed location of the SLN, pre- and
intraoperative use of the gamma probe (Neoprobe, Johnson&Johnson Medical,
Hamburg, Germany) to detect radioactivity and intraoperative detection of the
blue lymphatic vessels24,25.
Outline of the thesis
The main objectives of the studies of this thesis were to investigate the possibili-
ties to improve clinical practice and to reveal some of the consequences of the
introduction of the SLN procedure.
Intraoperative examination of the sentinel lymph node
After introduction of the SLNB, the biopsy is traditionally combined with the
lumpectomy or mastectomy of the diseased breast. A disadvantage of this proce-
dure is the need for a completion ALND as a delayed procedure, if metastatic dis-
ease is found in the SLN. Intraoperative examination might reveal the metastatic
disease, allowing immediate ALND. Techniques already in use are imprint cytol-
ogy and frozen section: each having its advantages and disadvantages. The frozen
section procedure is time consuming and might give rise to artefacts, but also
offers good visualisation. Imprint cytology offers cytological detail and preserves
tissue for definitive histopathology. A disadvantage is the higher chance for equiv-
ocal results. In chapter II, scrape cytology is introduced as a new technique. It
combines the tissue preservation and speed of cytology with a larger yield of cells
for examination compared with imprint cytology. The scrape cytology results
were compared with the definitive histopathologic results of the SLN in early
breast cancer patients. These results were further compared with the available
published results of intraoperative frozen section and imprint cytology examina-
tion.
9
Introduction and outline of the thesis
bw.schmidt  05-12-2005  14:23  Pagina 9
Sentinel lymph node biopsy under local anaesthesia
The intraoperative examination of the SLN, however, introduced substantial dis-
advantages, when compared to the certainties of the ALND-era. No single tech-
nique revealed all metastatic disease; accuracy varies from 78-98%. As a conse-
quence, reoperation for the completion ALND was necessary in 19% of the patients
with negative intraoperative examination results. Another disadvantage was the
time needed for intraoperative examination and the possible ALND in 30-40% of
the patients, which extended general anaesthesia duration and hampered opera-
tion room planning. Most of these problems could be tackled by performing the
SLNB under local anaesthesia. That way both clinician and patient are provided
with a histologic diagnosis before definitive breast and possible axillary surgery.
The aim of the study presented in chapter III was to evaluate feasibility of the
SLNB performed under local anaesthesia by comparing, among others, the SLN
detection rate under local and general anaesthesia. The technical addendum
more extensively describes the steps in the procedure of SLNB under local anaes-
thesia.
Axillary recurrence after a negative sentinel lymph node
biopsy
The presentation of an early breast cancer patient with regional recurrence after
a negative SLNB in the outpatient clinic presented a new problem. Several vali-
dation studies of SLNB all followed by an ALND published false-negative findings
varying from 0-22%. A meta-analysis of 13 studies reported a false-negative rate
of 5.1%. So, once the validation phase was completed, an unknown number of
patients with not-revealed tumour-positive nodes at SLNB did not undergo an
ALND. Undetected tumour-positive nodes of clinical importance are those lead-
ing to axillary recurrence. The clinical consequences of axillary recurrence after
a negative SLNB are not clear yet. In the ALND-era, 30% of the patients with axil-
lary recurrence presented with simultaneous locoregional or systemic metasta-
sis, 50% would develop distant metastasis in the future. Chapter IV describes the
incidence of axillary recurrence in current practice and literature. Prognostic fea-
tures of patients with an axillary relapse after a negative SLNB were analysed.
10
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Predicting the likelihood of non-SLN metastases 
utilizing a nomogram
Contrary to the problem of possible false-negative SLNB results, possibly leading
to axillary recurrence, the investigator finds oneself confronted with overtreat-
ment of the positive SLNB group. Several publications revealed that only in
approximately 50% of these patients, additional nodal metastases are detected in
the completion ALND. The SLN procedure already caused a 60% decrease of the
number of ALNDs in case of a negative SLN. However, a further reduction
through selection of a subset of patients with low suspicion for non-SLN metas-
tases after a positive SLNB seems possible. 
In order to quantify an individual patient’s risk for non-SLN metastases, a nomo-
gram was developed by the Breast Service of Memorial Sloan-Kettering Cancer
Center, New York. The nomogram was created using prognostic variables
assessed with multivariate logistic regression analysis. The outcome of the nomo-
gram is the predicted probability for the presence of non-SLN metastases. To
stimulate use in daily practice, the predicted probability can be calculated by a
website and a PDA compatible application. The aim of the study presented in
chapter V was to test the accuracy of the nomogram on a general population of
breast cancer patients in the Netherlands. 
Likelihood for non-SLN metastases: doctors versus numbers
The MSKCC nomogram was developed to identify the patient’s individual risk for
non-SLN metastases. In daily practice, clinicians raised objections against use of
the nomogram for several reasons. Patient’s age, as parameter to decide on per-
forming of a completion ALND or not, is not included in the nomogram, since it is
not a prognostic factor for non-SLN metastasis. However, age is felt by many surgi-
cal oncologists to be a determining factor. Further a low probability for non-SLN
metastasis after a positive SLNB makes a completion ALND dubious. This contra-
dicts the nowadays golden standard of a completion ALND after a positive SLNB. 
It is clear doctors can not balance all prognostic factors, each to their own weight,
and incorporate the results in their clinical decision making. It may therefore be
interesting to know how clinical predictions compare to the nomogram results
and how these nomogram results influence decisions clinicians take. Medical lit-
erature on both subjects is rare. The aim of the study presented in chapter VI was
to establish accuracy of surgical oncologists’ estimations for non-SLN metastases
compared with the MSKCC nomogram. Further the influence of the nomogram
on clinical decision-making was examined. 
11
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No evidence for increased angiogenesis 
in lymph node metastases after earlier surgical 
resection of a primary breast cancer
The phenomenon of accelerated growth of metastases after resection of the pri-
mary tumour has been described in animal models and patients. This observation
has been attributed to a changing balance between activators and inhibitors of
angiogenesis in favour of the first. Contributing factors are, among others, medi-
ators of normal wound healing. The aim of this study was to assess, whether
delayed SLNB after earlier resection of the primary tumour in breast cancer
patients would lead to increased angiogenesis of the SLN metastases. To this pur-
pose lymph node metastases of patients earlier operated on for primary breast
cancer, were compared for mean vascular density and proliferating endothelial
cells with a control, one-stage procedure, group. Further the fraction of prolifer-
ating cells in tumour and metastasis was examined. The results of this study are
presented in chapter VII.
In chapter VIII results and conclusions are summarised.
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Abstract
Background: Intraoperative examination of the sentinel lymph node (SLN) may
detect metastatic disease, allowing immediate axillary lymph node dissection and
therefore avoiding the need for reoperation. The aim of this study was to evalu-
ate the accuracy of scrape cytology of the SLN in patients with early breast can-
cer.
Methods: Sentinel node biopsy was performed in 148 patients with clinical T1-2
NO breast cancer. After harvesting, the SLN was bisected and cells from both
halves were scraped with a scalpel blade on to a slide and stained with a
Papanicolaou and Giemsa stain. Scrape cytology results were compared with the
results of paraffin sections stained with haematoxylin and eosin and with
immunohistochemistry. 
Results: The intraoperative diagnosis was correct in 126 patients (85%).
Sensitivity and specificity were 67 and 98% respectively; positive and negative
predictive values were 95 and 81%.
Conclusion: Scrape cytology is a useful method for intraoperative evaluation of
the SLN in patients with breast cancer.
16
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Introduction
The histological status of the axillary lymph nodes remains one of the most
important prognostic indicators in patients with breast cancer1. The sentinel
lymph node (SLN) has proven to be a reliable predictor of the histological status
of the remaining axillary lymph nodes2-6. SLN biopsy has the advantage of
decreased postoperative morbidity compared with complete axillary lymph node
dissection (ALND). A disadvantage is the need for reoperation if metastatic dis-
ease is found in the SLN.
Intraoperative examination of the SLN may detect metastatic disease, allowing
immediate ALND. Two techniques already in use for intraoperative examination
are frozen sectioning and imprint cytology. Frozen sectioning offers visualization
of architecture of the lymph node, but is tissue consuming and causes artefacts to
definitive pathology7,8. Imprint cytology offers cytological detail and preserves the
entire lymph node for definitive histopathology. Disadvantages include the small
number of cells sampled and the higher chance of indeterminate results caused
by atypical cells8,9.
Scrape cytology of the SLN is an alternative that combines the tissue preservation
of cytology with the advantage of a larger number of cells for examination8,10,11.
The aim of this study was to ascertain the value of intraoperative scrape cytology
in determining the histological status of the SLN in patients with early breast can-
cer.
Patients and methods
Between June 2000 and July 2001, 168 patients had a SLN biopsy for clinical stage
T1-2 NO breast cancer. In three patients the SLN procedure was not successful
and an ALND was performed in the same session. In 17 patients the SLNs were
examined only after operation. In the remaining 148 patients the SLN was exam-
ined during the operation by scrape cytology. The median age of these patients
was 56 (range 27-95) years. The pathological median tumour size was 16 (range
0-80) mm. The tumour stage was Tis in three patients (2%), T1 in 86 patients
(58%), T2 in 51 patients (34%), T3 in one (1%) and TO in seven patients (5%). In
26 patients an excision biopsy was performed before the SLN procedure.
Of the 148 patients, 109 (74%) had invasive ductal cancer (IDC), three (2%) had
in situ ductal cancer, 18 (12%) had invasive lobular cancer (ILC) and the remain-
ing 18 (12%) had intracystic papillary cancer, tubular cancer, metaplastic cancer,
Paget’s disease, medullary cancer or fibroadenoma.
SLN biopsy was performed according to Dutch guidelines using technetium-99m
17
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nanocolloid as a radioactive tracer and Patent blue dye (Bleu patente V; Guerbet,
Aulnay-sous-Bois, France) for lymphatic mapping; both were injected around the
tumour or around the scar when there had been previous excision biopsy3,12,13. At
operation a maximum of three sentinel nodes was sent to the pathology depart-
ment for examination by scrape cytology. If more SLNs were identified, only the
most suspicious were examined by scrape cytology. Each SLN was bisected, after
which cells from both sides were scraped with a scalpel blade on to a slide. The
material was fixed in 96% alcohol or air dried and subsequently stained with a
Giemsa and Papanicolaou stain. The slides were first screened by a cytological
technician and then reviewed by an experienced pathologist. The whole proce-
dure, including communication of the results, took about 20 min (figure 1).
The remaining node halves and other sentinel nodes were examined routinely by
embedding in paraffin, step sectioning at 500-µm intervals at three levels, and
staining with haematoxylin and eosin. If the SLN was negative on haematoxylin
and eosin staining, immunohistochemical staining at the three levels was per-
formed (figure 2). Cam5.2 is a monoclonal antibody directed against cytokeratin
18
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Figure 1 Scrape cytology: the enlarged cells are the tumour cells. Giemsa staining, magnification 200x.
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8 localized in the cytoplasm of the tumour cells (Becton Dickinson, San Jose,
California, USA).
Scrape cytology results were compared with routine and immunohistochemical
staining. Diagnostic accuracy, sensitivity and specificity, and positive and nega-
tive predictive values were calculated.
Results
A total of 268 SLNs were biopsied from 148 patients, a median of 2 (range 1-5) per
patient. Sixty patients (41%) were found to have metastatic involvement.
When evaluating the data per patient, 42 patients had at least one positive SLN
with scrape cytology. In two patients the SLN was positive on scrape cytology and
negative on histopathology. Both of these patients had a T1 tumour and IDC. In
40 patients with positive histopathology, scrape cytology of at least one SLN was
positive (sensitivity 67%). The specificity of scrape cytology of the SLN was 98%.
19
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Figure 2 The histology of a ductal carcinoma metastasis in a lymph node. Immunohistochemical stained with CAM 5.2.
Magnification 100x.
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The positive and negative predictive values were 95 and 81% respectively. The
overall accuracy of the scrape cytology procedure per patient was 85%. Results
per node were not calculated, because the consequences of scrape cytology are
taken at a patient level.
In 20 patients scrape cytology gave a false-negative result. This occurred in 14
patients with IDC (13% of all patients with IDC), four patients with ILC (22% of
all patients with ILC), and two patients with medullary and tubular cancer (11%
of all patients with other types of cancer). Ten of 20 patients with false-negative
scrape cytology results actually had micrometastasis in the SLN (defined as a
focus of 2 mm or less), as did seven of the 40 patients with positive scrape cytol-
ogy and histopathology findings. At subsequent ALND only four of 20 patients had
additional positive nodes: one extra, twice and two extra, twice. The mean num-
ber of positive nodes found with ALND was 0.2 for the group with negative scrape
cytology and positive histopathology, compared with 2.5 for the group with posi-
tive scrape cytology and positive histopathology.
Micrometastases were identified in 17 (28%) of 60 patients with metastatic dis-
ease14. Seven of these were found with scrape cytology and confirmed in the
haematoxylin and eosin-stained slide. In three patients, metastatic disease was
discovered only by immunohistochemistry.
Discussion
Several authors have already reported the results of intraoperative frozen sec-
tioning and imprint cytology of the SLN in patients with breast cancer. The mean
accuracy for frozen sectioning in the literature is 89%, with a range from 83 to
96%2,3,7,8,14,15. The mean accuracy for imprint cytology ranges from 78 to 98%,
with a mean of 91%15-18. The results of the various studies are difficult to com-
pare. They might be influenced by the lack of additional immunohistochemical
staining in three of ten studies and routine ALND in six of ten studies2,6,9,15,17,18.
Only two authors compared imprint cytology and frozen sectioning; they came to
different conclusions15,16(table 1). In the present study the accuracy of scrape
cytology per patient was 85%.
The distribution of metastases throughout the SLN is not uniform. At least 30% of
the metastases in a SLN might be missed with intraoperative examination by
scrape cytology after bisection of the SLN. In the present study metastatic disease
was diagnosed during operation in 40 patients (67%), which corresponds with the
findings of other authors. Two false-positive scrape cytology results were found,
both in patients with a T1 tumour and IDC. In both patients this was caused by an
interpretation error in the early phase of the trial19.
20
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In the present study, 28% of the patients with metastatic disease had micrometas-
tases in the SLN, similar to the results of other authors, who describe incidences
ranging from 12 to 51%5,8,9,19-21. The percentage of micrometastases found during
operation by frozen sectioning or imprint cytology in the literature varies widely
from 17 to 100%8,9,22. Rubio et al.9 reported micrometastases in only 12% of all
positive SLNs, all of which were found by imprint cytology. These results may
have been influenced by the lack of additional inununohistochemical staining
and routine ALND, which may influence a pathologist in describing `suspicious’
slides8,9. In the present study scrape cytology revealed seven of 17 cases of
micrometastatic disease during operation. Half of all false-negative results were
due to micrometastatic disease.
Finding a metastasis depends on its distribution and site in the SLN. The results
of scrape cytology might be improved by making further cross-sections of the SLN
(mean size 11 mm)15, although this will have limitations of thickness of the slide
(3-4 mm). This procedure would be time consuming and might destroy the mor-
phology of the SLN. Immunohistochemistry takes too long for an intraoperative
diagnosis.
In conclusion, scrape cytology yielded results similar to those of imprint cytology
and frozen sectioning of the sentinel node, and could be used for intraoperative
analysis of the SLN in patients with breast cancer.
21
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CHIDNLA enituoRstneitap fo .oN)%( ycaruccAeuqinhceTraeYecnerefeR
Motomura15 2000 FS 88 101 + +
IC 96 101 + +
Veronesi2 1997 FS 83 107 + +
Flett6 1998 FS 95 56 + -
Ratanawichitrasin17 1999 IC 98 55 + -
Rubio9 1998 IC 98 55 + -
Cserni18 2001 IC 78 60 + +
Van Diest16 1999 FS 96 54 - +
IC 82 54 - +
Weiser22 2000 FS 89 890 - +
Turner and Giuliano8 1998 FS 93 225 - +
Rahusen3 2000 FS 84 100 - +
Present series 2002 SC 85 148 - +
Table 1 Review of publications concerning intraoperative sentinel lymph node examination (Abbreviations: FS-frozen section-
ing, IC-imprint cytology, SC-scrape cytology, ALND-axillary lymph node dissection, IHC-immunohistochemical staining)
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Abstract
Background: A sentinel lymph node (SLN) biopsy in breast cancer patients, per-
formed under local anaesthesia (LA), could have advantages such as more effi-
cient use of operating room and pathologist’s time. It also provides a histologic
diagnosis before definitive breast surgery. The aim of this study was to assess fea-
sibility by comparing the results of SLN procedures performed under LA versus
general anaesthesia (GA). 
Methods: The SLN procedure was performed in 50 consecutive outpatients and
167 inpatients with clinical T1-2N0 breast cancer, while they were under LA and
GA respectively. The SLN detection rate, a comparison of mapped and harvested
SLNs, was compared for both groups. The duration of the SLN biopsies performed
under LA was measured.
Results: For both groups a median of two SLN/patient was harvested. The detec-
tion rate was 1.00 for the LA group and 0.99 for the GA group. The learning curve
for SLN procedures under LA shows a decrease in duration for the consecutive
months (not significant).
Conclusion: SLN biopsy can be safely and adequately performed under LA. It
allows early diagnosis of the lymph node status, acquired on an outpatient basis,
with minimal discomfort to the patient. The learning curve demonstrates that the
LA procedure can quickly be mastered if the surgeon is experienced in perform-
ing SLN biopsies.
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Introduction
The histologic status of the axillary lymph nodes is the most important prognos-
tic indicator in patients with breast cancer1. Sentinel lymph node (SLN) biopsy is
a reliable technique for axillary staging in clinical stage T1-2N0 breast cancer2-6.
An important advantage of SLN biopsy is its decreased risk of postoperative mor-
bidity compared with axillary lymph node dissection (ALND). Currently, the SLN
biopsy specimen is mostly examined intraoperatively by frozen section or imprint
cytology; if metastatic disease is identified, ALND is performed in the same ses-
sion.
Intraoperative SLN examination carries substantial disadvantages. No single
technique discloses all metastatic disease. As a consequence, reoperation is nec-
essary in 4 to 15% of patients with negative intraoperative examination results7-
11. Another disadvantage is that the time needed for intraoperative examination
extends the duration of general anaesthesia (GA) and, by consequence, the use of
the operating room12-15. Also, patients undergo surgery unsure of the exact diag-
nosis and the procedure that will be performed12,15. In theory, these problems
could be negated by performing the SLN biopsy with the patient under local
anaesthesia (LA). The outpatient procedure must meet the same standards of
quality as the operation it replaces14,16-18.
Outpatient SLN biopsy has possible advantages. A precise histologic diagnosis,
instead of the unsure result of intraoperative cytology or frozen section, can be
presented to the patient before definitive breast surgery is undertaken.
Furthermore, valuable operating room time is saved because SLN only requires
an outpatient surgical unit. Time constraints do not present an issue for the
pathologist with regard to the intraoperative diagnosis. Finally, approximately
15% of all patients will be spared a second episode of GA12-15,17-19. 
Still, one could also imagine some procedure-related complications. Patients may
experience discomfort as a result of the use of LA. The amount and type of local
anaesthesia used could also cause reactions and complications20. Theoretically,
injection of a local anaesthetic into tumour-bearing axillary tissue could intro-
duce tumour cells into the circulation12-14.
The present prospective study aims to evaluate the feasibility of the SLN biopsy
performed under local anaesthesia. For this purpose the results of 50 consecutive
SLN biopsies performed under LA and 167 consecutive SLN biopsies performed
under general anaesthesia were compared. 
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Patients and methods
Between February and June 2002, 50 consecutive patients underwent SLN biopsy
under LA in an outpatient setting (group LA). This group was compared with a
group of 167 inpatients, in which SLN biopsy was performed under GA from June
2000 until May 2001 (group GA). The first SLN procedure had already been per-
formed in May 1997. All patients presented with T1-2N0 breast cancer. 
Sentinel lymph node biopsy performed under local 
anaesthesia
The SLN procedure was performed using 60 MBq technetium-99m nanocolloid as
a radioactive tracer and 1 mL blue dye (Bleu patente V; Guerbet, Aulnay-sous-
Bois, France) diluted with 1 mL lidocaine (0.5%) for lymphatic mapping. In the
GA group, both were injected into breast parenchymal tissue surrounding the
tumour or biopsy cavity. In the LA group, the radioactive tracer was injected peri-
areolar in the diseased breast quadrant, and the blue dye was injected into the tis-
sue surrounding the tumour or biopsy cavity21.
In the LA patients, the SLN biopsy was performed in the outpatient operating
rooms. 
Patients were admitted 1 hour before the start of the procedure. No premedica-
tion was administered. Although the location of the SLN was marked on the skin
using the gamma probe (Neoprobe, Johnson&Johnson Medical, Hamburg,
Germany), the incision was standard, i.e., from the anterior to the dorsal axillary
line, just caudal to the axillary hairline, with an average length of 5 cm. Local
anaesthesia was administered by subcutaneous infiltration of lidocaine (0.5%)
with adrenaline (1:200.000). If needed, more anaesthetic was injected during
surgery, but it was always far less than the recommended safe dose20. The SLN
was identified and harvested intraoperatively guided by the lymphoscintigraphy,
the blue lymphatic vessels, and the detection of radioactivity by the gamma probe.
Haemorrhage was no problem because adrenaline and haemoclips were used22.
All patients left the hospital within 30 minutes after termination of the procedure.
A prescription for paracetamol was routinely given, but no patient made use of it.
Histologic examination of the sentinel lymph node
The SLN was bisected, after which both halves were embedded in paraffin. Each
part was step-sectioned at 500-micrometer intervals at 3 levels and stained with
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haematoxylin and eosin as well as immunohistochemical staining with Cam5.2.
Cam5.2 is a monoclonal antibody directed against cytokeratin 8, which is localized
in the cytoplasm of the tumour cells (Becton Dickinson, San Jose, California, USA). 
To assess the feasibility of SLN biopsy performed under LA, its results were com-
pared with those obtained after procedures performed under GA. The following
parameters were taken into consideration: detection rate of the SLNs, compari-
son of the number of SLNs harvested and detected by lymphoscintigraphy, num-
ber and type of complications, rate of lymph node metastases, and number of
lymph nodes detected in the complementary ALND if metastatic disease was
found in the SLN.
Results
The results of 50 consecutive patients undergoing SLN biopsy under LA in an out-
patient setting were compared with the results of 167 inpatients undergoing SLN
biopsy under GA. In 19 patients in the GA group and 3 patients in the LA group,
an excisional biopsy was performed before the SLN procedure.
The triple technique, consisting of static lymphoscintigraphy and intraoperative
use of the gamma probe and blue dye, was not complete in 25 GA patients. In 3
of these patients and 2 LA patients, the procedure was not successful because the
SLN was not visualised on lymphoscintigraphy; ALND was performed instead.
The median age of the patients of both groups was 57 years. The median histo-
logical tumour size was 16 mm for both patient groups (table 1).
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Table 1 Patient characteristics for LA and GA group (Abbreviations: LA - local anaesthesia, GA - general anaesthesia)
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For both groups, a median of two SLNs/per patients (range 1-4) was harvested.
All SLN biopsies in the LA group were performed or supervised by one surgeon.
The 2 participating surgical oncologists supervised the SLN procedures under
GA. In the 48 patients in the LA group (100%), all mapped SLNs were harvested.
In 99% of the GA patients (139 patients), all mapped, and in some cases more,
SLNs were found (not significant).
The SLN procedure under LA took a median of 30 minutes (range 15-95). In the
first month however, median duration was 42 minutes (range 25-95). The last
studied month showed a decrease in length of procedure to a median of 26 min-
utes (range 15-50). This decrease was not significant (P = 0.35, nonparametric
independent sample test-medians Fisher’s exact test). Only 1 LA procedure was
complicated by difficulty in identifying the SLN, but it resulted eventually in a
successful biopsy (4 SLNs) within 95 minutes. None of the LA patients had to be
admitted as a consequence of complications, and no GA biopsy was complicated
by technical difficulties (figure 1).
Metastases were identified in the SLNs of 12 LA patients (25%). In 7 patients
(15%) the outcomes demonstrated micrometastases, 58% of all metastatic dis-
ease. The SLNs from the GA group contained metastatic disease in 56 patients
(39%).  This involved micrometastases in 16 patients, 29% of all metastatic dis-
ease. Complementary ALND for both procedures contained a median of 11 lymph
nodes (range 3 to19) in GA patients and 12 (range 5-20) in LA patients (table 2).
The type of surgery used for procedures performed under GA was for 49 patients
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a simple mastectomy and was for 93 patients breast conserving surgery. The
numbers for LA patients were comparable (table 3). 
Lymphoscintigraphy of the LA group patients showed extra-axillary lymph nodes
in 5 subjects (10%); in 4 patients this involved an intramammary node, in 1
patient it involved an internal mammary node. One out of these 4 nodes located
in the breast parenchyma was harvested. In 10 patients (7%) of the GA group,
extra-axillary nodes were visualised on the lymphoscintigraphy. These included
3 intramammary nodes and 7 internal mammary nodes. Two of the nodes locat-
ed in the breast and 2 of the internal mammary nodes were identified.
Discussion
Few investigators have reported on SLN biopsy under LA. Fenaroli et al. present-
ed a successful feasibility study with 14 consecutive patients having early breast
cancer14. Alex and Krag performed a SLN procedure under LA in a patient with a
melanoma of the thigh17. Glass et al. and von Smitten mentioned the possibility
with both breast cancer and melanoma patients16,18. 
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Table 2 Results of the SLN and ALND procedures
(Abbreviations: ALN - axillary lymph node, ALND – axillary lymph node dissection, GA – general anaesthesia,
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Table 3 Breast surgery after SLN biopsy under LA or simultaneous with SLN biopsy under GA
(Abbreviations: LA - local anaesthesia, GA - general anaesthesia, BCT - breast conserving therapy)
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This feasibility study shows similar results for both groups concerning the num-
ber of harvested SLNs and the ratio comparing mapped and identified SLNs. The
operation time could be measured only for the LA procedures because the GA
biopsies were always combined with breast surgery. The learning curve for SLN
procedures under LA shows a progressive decrease in duration with cumulative
experience expressed for consecutive months, although this was not significant.
However, it demonstrates that the LA procedure can quickly be mastered if the
surgeon is experienced in performing SLN biopsies. Except for 1 long procedure
(resulting in 4 SLNs) in the early phase, no complications occurred.
A SLN procedure under local anaesthesia leads to more efficient use of the oper-
ating room, for one does not have to take into account the additional time possi-
bly needed for an ALND. Further it saves the pathologist time otherwise con-
sumed by intraoperative examination. It saves 15% of all patients a second
episode of GA and gives a histologic diagnosis instead of the uncertain result of
intraoperative examination14,16-18. Publications on the results of breast conserving
surgery under local anaesthesia report similar advantages12,13.  
Adverse reactions from infiltration of the anaesthetic were not encountered, nor
has this problem been mentioned in the literature12,13,15,19.  In our experience,
additional sedative was unnecessary. The amount of local anaesthetic used was
always far less than the recommended safe dose, and patients never used the pre-
scribed paracetamol. Because sedatives were not used, patients were able to
leave the hospital shortly after termination of the procedure. Additionally, the
possibility exists of introducing cancer cells into either the venous or lymphatic
circulation by injection of the local anaesthetic. Extrapolating from insights into
lumpectomy under LA and intratumoural injection of SLN tracers, leads one to
consider infiltration of the axilla a safe technique12.  
SLN biopsy under LA proved no more difficult than a procedure performed under
GA. However, performing complementary ALND after SLN biopsy done under LA
was more difficult. This was not reflected in the number of lymph nodes detect-
ed in the ALND. 
The radioactive tracer was injected in the LA group in the subareolar lymphatic
plexus. This injection mode assures a higher success rate of identifying a SLN by
lymphoscintigraphy, whereas less extra-axillary SLN are mapped scintigraphi-
cally21.  
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However, in 10% (5 patients) in the LA group, extra-axillary nodes were
mapped, but only 1 was harvested. In this patient it did not change adjuvant
treatment policy. 
In conclusion, SLN biopsy can be safely and adequately performed under LA on
outpatient basis. It allows early diagnosis of the lymph node status with minimal
discomfort to the patient. Further research concerning patient satisfaction and
cost issues is warranted.
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Abstract 
Background: Sentinel lymph node biopsy (SLNB) carries the inherent risk of
false-negative sampling. Undetected tumour-positive nodes of clinical impor-
tance are those that lead to axillary recurrence. This survey aims at clarifying the
extent of this problem in current practice and literature.
Methods: In a regional teaching hospital, 696 consecutive breast cancer patients
underwent SLNB between January 1998 and December 2003, and data were
entered in a prospective database. Thirteen studies dealt with the follow-up of a
cohort of sentinel lymph node (SLN)-negative patients or presented a case report.
Results: The SLN identification rate was 97.1%. The SLN was tumour free in 439
(65%) of the 676 patients. After a median follow-up of 26 months, axillary recur-
rence was detected in 2 of 439 patients, 4 and 27 months after the SLNB. The inci-
dence of clinically apparent false-negative SLNB is 0.46%. The systematic review
resulted in 3184 SLNB-negative patients with a median follow-up of 25 months.
Axillary recurrence occurred in 8 patients after a median of 21 months. The axil-
lary recurrence rate in the literature is 0.25%. One third of these patients pre-
sented with synchronous systemic metastases.
Conclusion: Axillary recurrences after a negative SLNB occur, but at a much
lower rate than would be expected on the basis of historical figures and the false-
negative SLN findings. The natural history of axillary relapse after negative SLN
biopsy resembles the locoregional recurrence of breast cancer.
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Introduction
The histological status of the axillary lymph nodes is the most important prog-
nostic factor in patients with breast cancer1. The sentinel lymph node biopsy
(SLNB) has proved to be a reliable alternative to the traditional axillary lymph
node dissection (ALND) with regard to predicting the histological status of the
remaining axillary lymph nodes in clinical T1-2N0 breast cancer2-6. The SLNB
has the advantage of reduced postoperative morbidity compared with ALND7. In
case of a positive sentinel lymph node (SLN), a complementary ALND is recom-
mended to maximise regional control and complete axillary staging. 
Several validation studies of SLNB’s followed by ALND in breast cancer patients
have been published. All these studies report the risk of false-negative sampling,
with rates varying from 0% to 22%2,6,8,-12. A meta-analysis of 13 studies including
912 patients reported a false-negative rate of 5.1%13. Once the validation phase is
completed, an unknown number of patients with undetected tumour-positive
nodes at SLNB do not undergo an ALND. Undetected tumour-positive nodes of
clinical importance are those that lead to axillary recurrence14.
Several questions arise considering axillary relapse. In the setting of a negative
SLNB, it would be interesting to identify prognostic factors for the incidence of
axillary relapse, especially regarding prevention. The clinical consequences for
the patient are unclear, and the nature of subsequent therapy is still open for
debate. 
The aim of this study was to identify the extent of this problem in current prac-
tice. The clinical consequences for the patients with recurrent axillary disease
were clarified. Furthermore, a systemic review of the literature was performed to
determine incidence, patient and tumour characteristics, and subsequent thera-
py.
Patients and methods
Between January 1998 and December 2003, 696 consecutive patients had a SLNB
for clinical T1-2N0 breast cancer in a regional teaching hospital. After a valida-
tion phase, in which 20 patients underwent SLNB with an ALND in the same pro-
cedure, patients with a tumour-free SLN did not undergo an ALND. In any case of
tumour involvement of the SLN, an ALND was performed. The follow-up consist-
ed of a physical examination every 3 months during the first 2 years and subse-
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quently every 6 months. All data were collected in a prospective database. The
median age of these patients was 57 years. The median tumour size was 16 mm.
The primary tumour was Tis in 22 patients (3%), T1 in 390 patients (56%), and
T2 in 243 patients (35%). The histological tumour type was invasive ductal can-
cer in 73% and invasive lobular cancer in 13% of the patients (table 1).
Lymphatic mapping and operative procedures
The SLN procedure was performed with 60 MBq of technetium-99m nanocolloid
as a radioactive tracer and 2 mL of blue dye (Bleu patente V; Guerbet, Aulnay-
sous-Bois, France) for lymphatic mapping. The SLN was identified and harvested
during surgery guided by lymphoscintigraphy, the blue lymphatic vessels, and
detection of radioactivity by the gamma probe. 
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Median age, y (range) 57 (20-95)
Tumour size, mm (range) 16 (0-65)
Primary tumour
             T0
             Tis
             T1
             T2
             T3
             T4
16 (2%)
22 (3%)
390 (56%)
243 (35%)
19 (3%)
6 (1%)
Histological type 
            IDC
            ILC
            Other
506 (73%)
90 (13%)
100 (14%)
Grade
            1
            2
            3
100 (17%)
282 (47%)
217 (36%)
Table 1 Patient and tumour characteris
tics of 696 SLNB patients 
(Abbreviations: SLNB – sentinel lymph node
biopsy, IDC - invasive ductal cancer, ILC -
invasive lobular cancer, Grade - Nottingham
combined histological grade)
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Pathologic examination of the SLN
The SLN was bisected, after which both halves were embedded in paraffin. Each
part was step-sectioned at 500-micrometer intervals at three levels and stained
with haematoxylin and eosin. Immunohistochemical staining was performed
with Cam5.2 (Becton Dickinson, San Jose, California, USA). 
Review of the literature
To determine the axillary relapse rate after a negative SLNB for breast cancer, a
systematic review of the literature was performed. Pubmed and the Cochrane
library were searched with the use of the Medical Subject Heading terms ‘breast
neoplasms’ and ‘sentinel lymph node biopsy’. This pair was linked to the terms
‘neoplasm recurrence’, ‘treatment outcome’ and ‘diagnostic errors’. This search
strategy resulted in 221 titles. Only 11 studies dealt with follow-up of a cohort of
SLN-negative patients or a case report on axillary relapse after negative SLNB in
breast cancer patients. Two other studies were found through links and refer-
ences.
Results
At least 1 SLN could be identified in 676 of 696 patients (97.1%). The median
number of harvested SLNs was 2 (range 0-9). In 237 of the 676 patients (35%) the
SLN contained metastatic disease. In 86 patients, this concerned micrometas-
tases. In 6 of these 86 patients with micrometastatic disease, an ALND was omit-
ted. 
After a median follow-up of 26 months (range 1-90), an axillary recurrence was
detected in 2 patients out of 439 with a negative SLNB. The incidence of axillary
relapse after tumour-negative SLNB was therefore 0.46%.
In one patient, physical examination revealed axillary lymph node recurrence 4
months after the SLNB. The ALND specimen contained two tumorous lymph
nodes. The patient received an aromatase inhibitor. In a second patient, axillary
relapse was detected by routine physical examination 27 months after the SLNB.
She underwent an ALND and ovariectomy and received tamoxifen. The SLNs of
these two patients were re-examined but did not reveal any metastasis. Patient
and tumour characteristics concerning these two patients are summarized in
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table 2. In a third patient with a 0.2 mm micrometastasis in the SLN, ALND was
omitted. Axillary recurrence was resected 22 months after the SLNB. Tumour was
found in the axillary fat and was not related to any preexistent lymph node struc-
ture. No technical problems were met during the ALND.
Pubmed and the Cochrane library search resulted in 10 studies concerning the
follow-up of a cohort SLN-negative patient with breast cancer and in 3 case
reports on axillary recurrence. The results of a total number of 3184 patients
(including the  present series) with a median follow-up of 25 months (range 16-
46) were pooled. In eight patients, an axillary relapse was diagnosed. This result-
ed in an axillary recurrence rate of 0.25% (table 3). Axillary relapse after nega-
tive SLNB of all 11 published cases occurred after a median of 21 months. The
data concerning these patients are listed in table 2. 
Discussion
Axillary recurrence after a negative SLNB in breast cancer patients is, at 0.46%,
rare in this group. The mean axillary relapse rate in comparable studies is equal-
ly low at 0.25%. These rates are far lower than would be expected if compared to
the false-negative rates of the SLNB in the validation phase; a meta-analysis
reported a false-negative rate of 5.1%13.  
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ypareht dna ecnerrucer yrallixAypareht dna ruomut yramirPStudy Age (y)
Primary
tumour
Type Grade Hormonal
receptor
Primary
surgery
Adjuvant
therapy
Axil.recur
(mo)
Syst.recur
(mo)
Systemic
therapy
Salmon21 47 T1a Medullary 2 Er-Pr- BCT Rt 19 No Rt + Ct
Blanchard22 SNoN14tCTSMSNSNSNSNSN
Loza23 41 T1a Idc 2 Er+Pr- BCT Rt + Ht 28 No Rt + Ct
Chung24 SNoN4SNSNSNSNSNc1T54
tCseY11SNSNSNSNSNc1T15
SNseY04tCTCBSNSNSNa1T84
Roumen25 46 T1b Idc 2 NS MST No 14 Yes Rt + Ht + ovariectomy
Estourgie26 44 T1c Idc 2 NS BCT Rt 21 No Rt + Ht
Yen27 tCoN42tCTSM-rP+rEANclIc1T75
tHoN4tHTSM-rP+rE3cdI2T57tdimS
35 T1c Idc 3 Er+Pr- MST No 27 No Ht + ovariectomy
Table 2 Patient and tumour characteristics of all patients in the literature with recurrent axillary disease 
(Abbreviations: Er - estrogen receptor, Pr - progesterone receptor, BCT - breast-conserving therapy, MST - mastectomy, Idc - inva-
sive ductal cancer, Ilc - invasive lobular cancer, Rt - radiotherapy, Ct - chemotherapy, Ht - hormonal therapy, NS - not stated, NA -
not applicable).
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These results are supported by follow-up studies of clinically node-negative
breast cancer patients in whom surgical axillary staging was omitted. A popula-
tion-based study showed that 34% of the axillary lymph nodes of clinical stage I
breast cancer patients contain metastases15. In contrast with these findings,
Greco and Fisher demonstrated that only 6.7% to 17.8% of the patients without
ALND developed axillary recurrence after a follow-up period of 5 to 10 years.
Axillary relapses were detected after a median period of 14.7 to 31 months16,17.
Hence, substantially fewer clinical recurrences were observed than would be
expected on the basis of data reported in literature.
Several factors can explain the difference between the false-negative rate of the
SLNB in the validation phase and the axillary relapse rates, as well as the lower
than expected axillary recurrence rate after omitting ALND. According to the
studies by Greco and Fisher, axillary relapse is to be expected, if it occurs, after a
median of 14.7 to 31 months at a follow-up of 63 to 126 months. The follow-up
period of the studies in the series in table 3 amounted to a median length of only
16 to 46 months and might therefore be too short to lead to comparable
results16,17. 
In contrast to earlier series, most patients currently receive adjuvant systemic
treatment because of tumour and patient characteristics. Adjuvant chemotherapy
has proved to destroy metastases in tumour-bearing axillary nodes and therefore
can be expected to decrease axillary relapse rates18. 
Another cause for the low relapse rate might be the decreasing incidence of fail-
ure to identify the SLN after the learning phase. A study with a longer validation
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Study Year of publication No. patients Study period Follow-up (mo) Axillary recurrence (% incidence)
Reitsamer28 0htnm 22 naeM10/2-99/56113002
Badgwell29 0htnm 23 naideM99/01-89/49513002
Estourgie26 2003 353 1/97-11/01 Median 16 mnth 1 at 21 mo (.3%)
Veronesi7 0htnm 64 naideM99/21-89/37613002
Schrenk19 0htnm 22 naideM00/9-69/6381002
Chung24 2002 206 1/98-12/01 Median 26 mnth 3 at 4/11/31 mo (1.5%)
Giuliano30 0htnm 93 naideM79/7-59/01760002
Roumen25 2001 100 12/97-6/00 Median 24 mnth 1 at 14 mo (1%)
Dessureault31 0htnm 02 naeM99/4-49/49080002
Blanchard22 2003 685 10/97-8/01 Median 29 mnth 1 at 41 mo (.1%)
Present series 2004 439 5/97-12/03 Median 26 mnth 2 at 4/27 mo (.5%)_
Table 3 Incidence of axillary recurrence after negative sentinel lymph node biopsy in breast cancer patients 
(No. patients - cohort of negative SLN patients)
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phase shows an increase in identifying the SLN from 67% with 18 patients to 96%
with 177 patients19. The false-negative rates from the published studies always
represent the validation phase. The studies reporting on the follow-up of SLN
negative patients have always passed this phase.
The young age of the patients with axillary recurrence is remarkable; almost all
patients in literature are younger (median 46 year) than the median age in this
series (median 57 year). This corresponds with the median age of 48 years of
patients with axillary relapse after ALND20. 
The clinical consequences for patients with axillary relapse after a negative SLNB
are yet unclear, but similarities to patients with axillary recurrence after ALND
are hard to overlook. In both groups, approximately 30% of the patients with axil-
lary recurrence present with simultaneous locoregional or systemic failure.
Approximately 50% of the patients with axillary relapse after ALND develop dis-
tant metastatic disease. This suggests an ominous prognosis for patients with
axillary relapse after a negative SLNB20.
It is therefore tempting to consider axillary relapse as a presentation of formal
locoregional recurrence. A patient with an axillary recurrence should therefore
receive therapy for locoregional failure.
In conclusion, axillary recurrences after negative SLNB occur, but at a much
lower rate than would be expected on the basis of historical figures and false-neg-
ative SLN findings. Considering the similarities to axillary relapse, subsequent
therapy should be aimed at locoregional and systemic control.
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Abstract
Background: According to Dutch guidelines, an axillary lymph node dissection
(ALND) is recommended whenever a sentinel lymph node (SLN) contains
metastatic disease. However, only in approximately 50% of patients with metasta-
tic disease in the SLN are additional nodal metastases detected in the completion
ALND. To identify the individual patient’s risk for non-SLN metastases, a nomo-
gram containing eight predictors was developed by the Breast Service of
Memorial Sloan-Kettering Cancer Center (New York, NY). The aim of this study
was to test the accuracy of the nomogram on a population of Dutch breast cancer
patients. 
Methods: Patient, tumour and SLN metastasis characteristics were collected of
222 consecutive patients who underwent a completion ALND. The data of the
index and test population were compared. A receiver operating characteristic
curve was drawn, and the area under the curve was calculated to assess the dis-
criminative power of the nomogram.
Results: Even though our patient population differed in many respects from the
source population, the area under the receiver operating characteristic curve
amounted to 0.77, a value very much comparable to the one found in the source
population.
Conclusion: The nomogram provides a fairly accurate predicted probability for
the likelihood of non-SLN metastases in a general population of breast cancer
patients at a regional teaching hospital in The Netherlands. This suggests that the
nomogram’s originally calculated predictive accuracy may be valid for patient
populations that differ considerably from the population in which it was devel-
oped. 
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Introduction
The histological status of the axillary lymph nodes is the most important prog-
nostic indicator in patients with breast cancer1. The sentinel lymph node (SLN)
procedure is a reliable technique for assessing axillary lymph node involvement
in clinical T1-2N0 breast cancer2-7. The morbidity of an axillary lymph node dis-
section (ALND) can be avoided in case of a histopathologically negative SLN8. In
case of a SLN containing metastatic disease, however minimal, prevailing Dutch
guidelines recommend an ALND.
A completion ALND is performed for staging, achieving regional control, and
improving survival9-13. Accurate staging requires information on the total number
of nodes involved14. Opponents of a routine ALND after tumour-positive SLN
biopsy (SLNB) argue that the added therapeutic benefit is low15. In earlier arti-
cles, only in approximately 50% of patients with metastatic disease in the SLN
were additional nodal metastases detected in the completion ALND16. A study on
the follow-up of 31 SLN-positive patients who declined a completion ALND,
showed no axillary recurrences after a mean follow-up of 30 months. All patients
had received adjuvant chemotherapy and breast and chest wall radiation17. This
is in accordance with the present guidelines, which recommend that virtually all
SLN-positive patients should receive adjuvant chemotherapy. This, in combina-
tion with radiotherapy, might eradicate residual metastatic disease18.
After the introduction of the SLNB, several studies addressed the predictors of
non-SLN metastases after a positive SLNB. To identify the individual patient’s risk
for non-SLN metastases, a nomogram was developed by the Breast Service of
Memorial Sloan-Kettering Cancer Center, New York (figure 1). A nomogram is a
graphical tool to depict a complicated calculation19. The association of prognostic
features with the likelihood of non-SLN metastases was assessed by multivariate
logistic regression analysis of a retrospective group of 702 patients. The nomo-
gram was created using pathologic size, tumour type and nuclear grade, lympho-
vascular invasion, multifocality, estrogen receptor status, method of detection of
the SLN metastases, number of positive SLNs and number of negative SLNs. The
outcome of the nomogram is the predicted probability of non-SLN metastases.
This predicted probability can be determined graphically or, to facilitate use in
daily practice and with greater accuracy, can be calculated by the Web site
www.mskcc.org/nomograms or through a personal digital assistant-compatible
application. The nomogram was validated in a prospective set of patients from
MSKCC. It reasonably accurately predicted the probability of non-SLN metastases
for an individual breast cancer patient with a positive SLN at MSKCC. 
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The aim of this study was to assess the nomogram’s generalisibility, by testing its
predictive accuracy in a population of breast cancer patients from a regional
teaching hospital in The Netherlands. 
Patients and methods
Between January 1998 and December 2003, 696 consecutive patients underwent
a SLNB for a clinical T1-2N0 breast cancer in a teaching hospital. Data concern-
ing these patients were prospectively collected in a breast cancer database. The
SLNB revealed metastatic disease in 229 patients (33%). Almost all (n=222) of
these patients underwent a completion ALND. To be included in the study popu-
lation, patients had to meet the following selection criteria: (1) the patient had to
undergo an operation for a primary invasive breast cancer, without neo-adjuvant
therapy; (2) the SLNB had to be successful, and the SLN had to contain any
amount of metastatic disease; and (3) the total lymph node count of SLNB and
ALND had to be at least 10. From 47 (24%) of the 222 patients, fewer than 10
lymph nodes were retrieved.
SLN identification
The SLN was identified by using 60 MBq of technetium-99m nanocolloid as a
radioactive tracer before surgery and 2 ml of blue dye (Bleu Patente V; Guerbet,
Aulnay-sous-Bois, France) for lymphatic mapping. During surgery, the SLN was
harvested guided by the triple technique consisting of preoperative lym-
phoscintigraphy, blue lymphatic vessels, and detection of radioactivity by gamma
probe (Neoprobe; Johnson&Johnson Medical, Hamburg, Germany).
SLN histopathological examination
The SLN was bisected, after which both halves were embedded in paraffin. Each
part was stepsectioned at 500-micrometer intervals at three levels and stained
with haematoxylin and eosin (H&E), and immunohistochemical (IHC) staining
with Cam5.2. Cam5.2 is a monoclonal antibody directed against cytokeratin 8,
which is localized in the cytoplasm of the tumour cells (Becton Dickinson, San
Jose, California, USA). The nomogram differentiates in three or four methods of
detection of metastatic disease in the SLN: IHC only, serial, routine H&E and pos-
sible frozen-section. Since SLNs in this study were retrieved with use of local
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anaesthesia, the nomogram without the frozen-section method of detection was
used. No distinction was made in the database between serial and routine H&E,
and therefore all slides were reviewed by an experienced pathologist. If the first
slide was positive, it was judged as routine H&E positive. Metastases found on fur-
ther slides were judged as serial H&E or IHC positive, depending on the method
of detection.
Data analysis
Patient and tumour characteristics were collected from the prospective database
for each variable of the MSKCC nomogram, including tumour type (ductal vs. lob-
ular carcinoma), pathological size (cm), and nuclear grade, presence of lympho-
vascular invasion, multifocality, estrogen receptor status, method of detection of
the SLN metastasis (routine histopathology, serial H&E or IHC) and number of
49
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Figure 1 The nomogram to predict the likelihood of non-SLN metastases after a positive SLN biopsy, as developed by MSKCC.
NUCGRADE, tumour type and nuclear grade (ductal, nuclear grade I; ductal, nuclear grade II; ductal, nuclear grade III; lobular); LVI,
lymphovascular invasion; MULTIFOCAL, multifocality of primary tumour; ER, estrogen-receptor status; NUMNEGSLN, number
of negative SLNs; NUMSLNPOS, number of positive SLNs; PATHSIZE, pathological size in cm; METHDETECT, method of detec-
tion of SLN metastases (routine H&E, serial H&E and IHC). The first row (POINTS) is the point assignement for each variable. Row
2-9 represent the variables included in the model. For an individual patient, each variable is assigned a point value (uppermost scale,
POINTS) based on the histopathological characteristics. A vertical line is made between the appropriate variable value and the
POINTS line. The assigned points for all eight variables are summed and the total is found in row 10 (TOTAL POINTS). Once the
total is located, a vertical line is made between TOTAL POINTS and the final row 11. Row 11 presents the predicted probability for
non-SLN metastases after a positive SLN biopsy.
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Prospective Group
CWH
(N = 222)
Prospective Group
MSKCC
(N= 373)
P-value
N % N %
Age
1.247511.538705  0.11
9.756129.4644105 >     
Pathologic Size (cm)
5.3315.015.0  0.01
1.31949.5310.1-6.0     
5.446615.04090.2-1.1     
9.42391.13960.3-1.2     
0.11140.81040.5-1.3     
9.2110.491.5
Tumour type and nuclear grade
9.2115.3103I ,latcuD     0.001
9.645711.5387II ,latcuD    
6.439213.9256III ,latcuD    
5.51851.2294raluboL    
Lymphovascular invasion
7.859126.76051oN     0.039
3.144514.2327seY    
Multifocal
6.461422.57761oN     0.010
4.532318.4255seY    
Estrogen-receptor status
3.22384.4123evitageN     0.025
7.770926.58091evitisoP    
Method of detection
8.4811.2294ylnO CHI     0.001
7.01041.7183E&H laireS    
4.976928.06531E&H enituoR    
No. of positive SLNs
175624.373611     1.0
1.02576.12842    
6.5121.373    
1.284.134    
8.03005    
005.016    
00007    
3.01008
No. of negative SLNs
4.53231951310     0.001
2.12978.82461    
3.91276.8912    
0.11141.373    
9.522004    
9.175.015    
7.201006    
5.02007    
1.28008
Table 1 Comparison of descriptive characteristics of both prospective patient populations of the CWH and MSKCC. 
(Abbreviations: CWH – Canisius Wilhelmina Hospital, MSKCC – Memorial Sloan-Kettering Cancer Center, SLN - sentinel lymph
node, IHC – immunohistochemical staining, H&E - hematoxylin and eosin)
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positive and negative SLNs (figure 1). These characteristics were compared with
the prospective MSKCC data and tested for significance (table1). 
By using the MSKCC Web site, the predicted probability was calculated for each
patient. The 222 patients were grouped in deciles (groups of 22 patients) accord-
ing to their predicted probabilities. For each group, the actual probability was cal-
culated by assessing the incidence of additional non-SLN metastases. A calibration
plot was drawn showing for each decile the actual versus predicted probability. To
measure the discrimination of the nomogram, a receiver operating characteristic
(ROC) curve was constructed and the area under the curve was calculated.
Calculations were performed for the entire cohort (n = 222) and for the cohort
excluding patients for whom fewer than 10 lymph nodes could be retrieved (n =
167). All analyses were conducted with SPSS 11.0 (SPSS Inc., Chicago, IL)
Results
Patient and tumour characteristics were collected and compared with the MSKCC
data. All variables differed significantly except age and the number of positive
SLNs (table 1). Among the 47 patients from whom fewer than 10 lymph nodes
were retrieved, the median number of lymph nodes was 8.
To assess the accuracy of the nomogram, actual probabilities were plotted against
the calculated predicted probability for each decile of patients. The trend line
shows almost complete concordance, with the ideal line with a slope of 1 (figure 2).
A ROC curve was drawn to assess the discrimination of the nomogram (figure 3).
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Figure 2 Calibration plot for
the nomogram. The entire cohort
of 222 patients was classified in
deciles according to their predict-
ed probabilities. For each group,
the actual probability (incidence
of additional non-SLN metas-
tases) was calculated. A calibra-
tion plot was drawn showing for
each decile the actual versus pre-
dicted probability.
(Abbreviations: non-SLN – non
sentinel lymph node)
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The area under the ROC curve (AUC) was 0.76 (95% confidence interval, 0.69-
0.83). Both graphics and statistical analysis were repeated after exclusion of the
patients in whom fewer than 10 lymph nodes were recovered. As a result, the cal-
ibration plot shifted to the left, and the AUC amounted to 0.77 (95% confidence
interval, 0.70-0.84) (figure 4).
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Figure 3 A receiver operating
characteristic curve assessing
the discrimination of the nomo-
gram. The area under the ROC
curve is 0.76. 
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Figure 4 Calibration plot for
the nomogram. The cohort of
167 patients in whom 10 or more
retrieved lymph nodes could be
retrieved were classified in
deciles according to their pre-
dicted probabilities. For each
group, actual probability (inci-
dence of additional non-SLN
metastases) was calculated. A
calibration plot was drawn
showing for each decile actual
versus predicted probability
(Abbreviations: non-SLN – non
sentinel lymph node)
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Discussion
Soon after the validation phase of the SLN concept, several articles were pub-
lished concerning prognostic factors for non-SLN metastatic disease after a posi-
tive SLNB. Various predictors were identified, such as a palpable breast mass,
tumour size, histological grade, lymphovascular invasion, SLN micrometastasis
or size of the nodal metastasis, extranodal extension, and more than one positive
SLN16,20-31. The MSKCC nomogram combines these prognostic factors, revealed
by multivariate analysis. The nomogram is a tool that provides a risk estimate for
the likelihood of non-SLN metastases and can be used in current practice. 
Because the nomogram was developed in MSKCC, which is a tertiary referral
center, the question arose whether it would be applicable to the population of a
Dutch regional teaching hospital. The difference of the studied populations was
reflected in significantly deviating patient and tumour characteristics. The area
under the curve, however, amounted to 0.76 in the Dutch population for the
entire group and to 0.77 for the group comparable to the source group. For the
New York group, the area under the curve was 0.78. The scale of the area under
the curve ranges from 0.5 for a test as good as the toss of a coin, to 1.0 which
makes a perfect test. An area under the curve of 0.77 is therefore a reasonably
accurate predictive test.  
According to the MSKCC inclusion criteria, at least 10 lymph nodes need to be
retrieved. This criterion was not met in 24% of the Dutch patients. The likelihood
for detecting a non-SLN containing metastatic disease increases with the number
of examined nodes. A higher yield of nodes per patient would therefore result in
a shift of the calibration plot to the left. Our data suggest, however, that the influ-
ence of the number of retrieved lymph nodes is minimal and should not preclude
use of the nomogram.
Recently a study was presented that compared surgeons’ predictions of the prob-
ability of non-SLN metastatic disease with the performance of the MSKCC nomo-
gram. The surgeons’ predictive accuracy corresponded with an area under the
curve of only 0.54. Clearly, the MSKCC nomogram outperformed expert judg-
ment, thus emphasising its clinical utility32. 
The observed differences in patient populations can be explained by the function
of the hospitals: MSKCC is an oncologic referral center and the Canisius
Wilhelmina Hospital is a regional teaching hospital for the general population.
The higher incidence of smaller tumours at MSKCC could be the result of annu-
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al screening for breast cancer in all patients, compared with the Dutch screening
scheme, which consists of 2-yearly screening of women aged 50 to 75 years.
Approximately 30% of the study patients had a screening-detected tumour.
Except size, all other tumour characteristics had a better profile in the Dutch pop-
ulation, which corresponds to a more general patient population mix. 
A subset of 40%, of the 50% of the breast cancer patients with a SLN containing
metastatic disease, will have non-SLN metastases. Consequently, a cutoff value of
10% predicted probability would concern 2.0% of all patients. According to the
predicted probability of 10%, only 0.2% would be at risk for residual metastatic
disease in non-SLNs. Axillary recurrence rates after negative SLNB are so far
lower than expected. This may be explained by the increasing number of patients
in this group receiving adjuvant therapy18,33. Patients with a SLN containing
metastatic disease will always be considered for adjuvant therapy. As a conse-
quence, axillary recurrence rates will even be lower than expected, and a cutoff
point of 10% seems therefore reasonable and defensible. In current practice, the
nomogram was used to avoid completion ALND in several patients with a low
likelihood (<10%) for non-SLN metastases. The Dutch guidelines, however, rec-
ommend a completion ALND for all patients in the presence of only one prog-
nostic factor, a positive SLN. This nomogram enables the formation of an indi-
vidualized risk estimate for the probability of non-SLN metastases based on eight
predictors. The nomogram does not make a statement on treatment recommen-
dations. Its results can support the multispecialty oncologic team as well as doc-
tor or patient regarding the choice of whether an ALND is desirable, taking into
account, for instance, patients’ preferences and risk aversiveness. Further
research on estimates for non-SLN metastases by oncologists versus the MSKCC
nomogram is warranted.
In conclusion, the nomogram provides a fairly accurate prediction of the proba-
bility of non-SLN metastases in a general population of breast cancer patients, dif-
fering from the population in which the nomogram was originally developed. The
resulting risk estimate can help to individualise a patient’s treatment.
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Abstract
Background: In approximately 40% of the breast cancer patients with sentinel
lymph node (SLN) metastases, additional nodal metastases are detected in the
completion axillary lymph node dissection (cALND). The MSKCC nomogram can
help to quantify a patient’s individual risk for non-SLN metastases with fairly
accurate predicted probability. 
The aim of this study was to compare the predictions of surgical oncologists for
non-SLN metastases with nomogram results and to clarify the impact of nomo-
gram results on clinical decision making.
Methods: Questionnaires were sent to surgical oncologists involved in breast can-
cer care. It contained 10 scenarios presenting female breast cancer patients with
a positive SLN and relevant prognostic features. The surgeon was asked to pre-
dict the probability for non-SLN metastases for the first 5 scenarios. For the
remaining scenarios, the patient’s actuarial likelihood, calculated by the nomo-
gram, was supplied. The surgeon was asked whether or not (s)he would perform
a cALND. The type of hospital and the surgeon’s experience were registered.  
Results: 107 Questionnaires were returned, coming from 8 out of 10 academic or
cancer centres, 29 out of 41 regional teaching hospitals and 19 out of 61 local hos-
pitals. The concordance-index amounted to 0.78, indicating moderate concur-
rence. The intersurgeon variation was important. About 25% of the surgeons was
influenced by nomogram information and decided in one or more patients to
abandon the cALND. Neither the type of hospital nor experience influenced pre-
dicting abilities or the clinical decision making process.
Conclusion: Individual predictions of surgical oncologists for non-SLN metastases
do not correlate well with the MSKCC nomogram. The distribution between inter-
surgeon predictions for one scenario is important. Therefore the nomogram is
superior to clinical estimations for predicting the likelihood for non-SLN metas-
tases.
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Introduction
The sentinel lymph node biopsy (SLNB) is now widely accepted as an accurate
staging procedure in breast cancer patients1-4. If any amount of metastatic disease
is found in the sentinel lymph node (SLN), a completion axillary lymph node dis-
section (cALND) is recommended according to the Dutch guidelines to optimize
ultimate staging, regional control and survival enhancement5-7. When the SLN is
tumourfree, patients can be spared a cALND and its morbidity in terms of lym-
phedema, seroma formation, reduced shoulder motility and chronic pain8,9. 
In approximately 40% of the breast cancer patients with SLNs containing
metastatic disease, additional nodal metastases are detected in the cALND10-23.
The SLN procedure already caused a decrease of the number of ALND in case of
a negative SLN. A further reduction could be achieved through selection of a sub-
set of patients with low suspicion for non-SLN metastases after a positive SLNB.
Many authors determined factors that attempt to predict the presence of non-
SLNs containing metastatic disease. The most frequently identified predictors are
the size of the primary tumour (size in general12,16,22-24 and size larger than
2cm14,17,19,20) and SLN  metastasis (size in general10,12,16,17,23 and macrometasta-
sis13,14,18-20), extranodal growth10,13,15,24 and lymphovascular invasion10,14,20-22,24.
Some authors identified subsets with such a small risk for non-SLN metastases
that an ALND could safely be omitted, but all concerned small studies and subset
groups of patients24. Several groups emphasize the importance of the ongoing
trial of the American College of Surgeons (Z0011), in which patients with a posi-
tive SLN are randomized to ALND or no further axillary treatment. The aim of
this trial is to reveal a subset of patients in which an ALND can be omitted.
The MSKCC breast cancer group used the relevant predictors to develop a nomo-
gram to help quantify a patient’s individual risk for non-SLN metastases (figure
1). It provides a reasonably accurate predicted probability and was validated for
a general population of Dutch breast cancer patients11,22. 
For daily practice, however, it is essential to know how clinical predictions com-
pare to the nomogram results and how these nomogram results influence deci-
sions clinicians take. Comparisons of clinical versus computer-aided decision
making are rare in medical literature. One author examined prostate nomogram
results against urologists’ predictions. He concluded, that nomogram results
could be of significant benefit in certain settings of clinical decision making25.
Almost no literature could be found about the influence (nomogram) results have
on clinical decision making26. To this purpose a systematic search in Pubmed
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under the MeSH-terms ”forecasting, outcome assessment and breast neoplasms”
and the heading “clinical decision making” was performed.
The aim of the first part of this study was to establish the surgical oncologists’
estimate or “guesstimate” for axillary lymph node involvement after a positive
SLN biopsy in breast cancer patients. These findings were compared with the
MSKCC nomogram results. The second part of this study should clarify to what
extent the additional information provided by the nomogram, influences clinical
decision making.
Patients and methods
To examine clinical predictive ability, a questionnaire was sent to all surgical
oncologists involved in breast cancer care in the Netherlands. It contained ten
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Figure 1 The nomogram to predict the likelihood of non-SLN metastases after a positive SLN biopsy, as developed by MSKCC.
NUCGRADE, tumor type and nuclear grade (ductal, nuclear grade I; ductal, nuclear grade II; ductal, nuclear grade III; lobular); LVI,
lymphovascular invasion; MULTIFOCAL, multifocality of primary tumor; ER, estrogen-receptor status; NUMNEGSLN, number of
negative SLNs; NUMSLNPOS, number of positive SLNs; PATHSIZE, pathological size in cm; METHDETECT, method of detec-
tion of SLN metastases (routine H&E, serial H&E and IHC). The first row (POINTS) is the point assignement for each variable. Row
2-9 represent the variables included in the model. For an individual patient, each variable is assigned a point value (uppermost scale,
POINTS) based on the histopathological characteristics. A vertical line is made between the appropriate variable value and the
POINTS line. The assigned points for all eight variables are summed and the total is found in row 10 (TOTAL POINTS). Once the
total is located, a vertical line is made between TOTAL POINTS and the final row 11. Row 11 presents the predicted probability for
non-SLN metastases after a positive SLN biopsy.
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scenarios presenting female breast cancer patients with a positive SLN and added
relevant prognostic features. An example of a scenario is presented here. 
“What is the likelihood for residual disease in the axilla in a 50 year old female
with a 3 cm centrally located multifocal tumour. Tumour characteristics are inva-
sive ductal cancer, nuclear grade II, estrogen and progesteron receptor negative
and no sign of lymphovascular invasion. 1 out of 2 SLNs is positive by immuno-
histochemical staining.”
In addition to the data required to use the nomogram, age, location of the tumour
and progesteron-receptor status were supplied. The surgeon was asked to esti-
mate the probability for non-SLN metastases for each of the first five scenarios.
The accuracy of the surgical oncologists’ prediction was established by compar-
ing the results with the nomogram findings.
For the second five similar scenarios, the patient’s individualized predicted prob-
ability for metastatic disease in non-SLNs, calculated by the nomogram, was sup-
plied. To clarify the impact of the nomogram results on clinical decision making,
the surgeon was asked whether or not (s)he would perform a cALND, not taking
into account the Dutch breast cancer guidelines5,27.  
Clinicians completing the questionnaire provided the type of hospital they
worked at: academic or cancer centre, regional teaching or local hospital.
Surgical experience -expressed in years after graduation from medical school- of
each surgeon was registered28. To examine the influence of experience on pre-
dicting abilities, years were transposed to a number of decades.
An experienced statistician performed all statistical analyses with help of the sta-
tistical package SAS for Windows release 8.02.
Results
107 Questionnaires were returned, coming from 8 out of 10 academic or cancer 
centres, 29 out of 41 regional teaching hospitals and 19 out of 61 local hospitals. 
The nomogram predicted probability for the first five consecutive scenarios was
4, 10, 10, 32 and 43%.  The median clinical guesstimate was 10, 10, 15, 30 and
30% (figure 2). A concordance-index was calculated to demonstrate concordance
or discorcordance between the sequence of nomogram results and clinical esti-
mates. The c-index scale varies from 0.5, which represents any toss of a coin, to
1.0, which represents perfection. The c-index in this study amounts to 0.78 indi-
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cating moderate concurrence. The variation between the predictions of the indi-
vidual surgeons for each scenario was important, minimum and maximum val-
ues varied from 2,5-90 to 0-100% (figure 3). There is no significant difference
between the predictions of surgical oncologists of the various types of hospitals.
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Experience did not make a difference in clinical predicting abilities either.
Several models were used to test both relationships but no correlation could be
found (P>0.20, always).
In the second part of five scenarios, the surgical oncologist determined on the
basis of the clinical data and the supplied nomogram results, if (s)he would per-
form a cALND. The likelihood for non-SLN metastases was 7, 8, 14, 21 and 44%.
Surgical oncologists considered the need for a cALND 90, 78, 88, 95 and 99% (fig-
ure 4). About 25% of the surgeons was influenced by the information supplied by
the nomogram and decided in one or more patients to abandon the cALND
despite the positive SLN. The type of hospital, a surgeon works at, or the experi-
ence, did not seem to influence the clinical decision making process (P>0.20,
always).
Discussion
Clinical and actuarial predictions concerning non-SLN metastasis after a positive
SLN biopsy in breast cancer patients do not correlate well. The distribution of
clinical predictions of the individual surgeon per scenario is important as shown
in figure 3.
The similarity of the bar heights in figure 2 is striking in scenario B, C and D. The
‘median’ surgical oncologist can discriminate the likelihood for non-SLN metas-
tases for the various scenarios. When compared with figure 3, however, the inter-
observer variability is as striking. The individual surgical oncologist, how experi-
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enced (s)he may be, is not able to make a solid prediction of the need for a
cALND. The type of neither hospital nor the clinical experience influenced pre-
dicting abilities. 
For some scenarios, the difference between clinical and actuarial prediction is
more than mean. This cannot be explained by the age or other variables of the
patients in question. 
In the second part of the questionnaire, the influence of the actuarial probability
on clinical decision making was determined. Of all surgeons, about 25% appears
to be influenced by the nomogram results. This could not be attributed to the type
of hospital or clinical experience.  
The bar heights lines in figure 4, presenting the actuarial likelihood for non-SLN
metastases and the percentage surgical oncologists abandoning the cALND, have a
similar upward course. For the first scenario, however, the clinical considered need
for a completion ALND and actuarial likelihood for non-SLN metastases deviate
widely. This is probably caused by the young age of this patient, 28 years, compared
to the mean of 51 years of the other patients in this part of the questionnaire. 
One author described several studies comparing actuarial and clinical predic-
tions26. Actuarial predictions always exceeded the mean accuracy of the clini-
cians and even the single best clinical prediction. Providing of the actuarial pre-
diction resulted in clinicians’ improvement, but never matched the calculated
prediction. Exceptions occur in case of very rare events. In a scenario of this
questionnaire, the young age of one of the patients may have been regarded by
various surgical oncologists as rare. None of the studied articles, however, judged
age as a predictive variable for non-SLN metastasis10,12-16,18-23. Human judgement
is coloured by many factors. Fatigue, recent experience, changes in order of
information, overconfidence in one’s clinical judgement, inability to distinguish
between valid and invalid variables and the weight of various variables influence
clinical prediction. Further a tendency exists to overrate information consistent
with one’s hypothesis and ignore contradictory information26,29.
Experience of clinicians influences diagnostic and therapeutic performance. A
study on diagnostic skills of general practitioners in the first moment of consul-
tation demonstrated a strong correlation between experience and diagnostic per-
formance30. Another study proved an inverse relationship between experience
expressed as the number of years since graduation of medical school and perfor-
mance of internists31. A third author determined that time in practice as well as
type of hospital had an influence on physician performance. A physician would
perform optimal between six and 15 years after graduation in a large, multispe-
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cialty group32. A recently published systematic review reported a decrease in per-
formance with increasing experience in more than half of the examined studies28.
A possible drawback in this study could be that experience in treating a specific
condition may not be necessarily correlated to the number of years after gradua-
tion. The present study, however, could not detect any relation between predict-
ing abilities and clinical experience, nor the type of hospital, where the intervie-
wee worked.
Concluding, it is stated that the individual predictions of surgical oncologists for
non-SLN metastases do not correlate well with the MSKCC nomogram. The dis-
tribution between predictions of individual surgeons for one scenario is impor-
tant. Therefore the nomogram outperforms expert judgement.
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Abstract  
Background: The phenomenon of accelerated growth of metastases after resec-
tion of the primary tumour has been described in animal models and patients. It
has been attributed to a change of balance between activators and inhibitors of
angiogenesis in favour of the first. Other contributing factors are mediators of
normal wound healing. The aim of this study was to assess, whether delayed sen-
tinel lymph node (SLN) biopsy after earlier resection of the primary tumour in
breast carcinoma patients would lead to increased angiogenesis of the SLN
metastases.
Methods: From 222 patients operated on for breast carcinoma between January
2000 and July 2001, 5 patients underwent a diagnostic excision biopsy at first and
a SLN biopsy later, which revealed macrometastases. To quantify angiogenesis in
the SLN metastases, the density of microvessels (MVD) and percentage prolifer-
ating vascular endothelial cells was determined in all patients by sequential dou-
ble immunohistochemistry. Further the proliferating index for primary tumour
and SLN metastases was established. These parameters were compared to
matched controls.
Results: The median delay for SLN biopsy was 35 days. No statistically significant
difference was identified in the comparison of the endothelial proliferating index
and MVD between the matched pairs of patients. Also no significant difference
was found in a comparison of the proliferating index of the primary tumour with
the lymph node metastases for both groups of patients.
Conclusion: These data cannot objectify an increase of angiogenesis or tumour
proliferation of the lymph node metastases after resection of the primary tumour.
Since a high MVD is related to decreased overall survival, this might suggest that
prognosis was not influenced.  
72
Chapter 7
bw.schmidt  05-12-2005  14:23  Pagina 72
Introduction
Patients with breast carcinoma sometimes require multiple operations; especial-
ly if the first operation is a diagnostic excisional biopsy in case of low suspicion
for malignancy. They might even have to suffer from preoperative waiting lists,
influencing the length of the period in between the subsequent operations. Little
is known about the effect of the combination of primary resection and delay on
growth rate of lymph node metastases on short term.    
Angiogenesis, the sprouting of new capillaries from existing vessels, is a complex
process and essential to the growth of primary and metastatic tumour beyond the
diameter of 1-2 mm3 1. Angiogenesis is a result of an imbalance between pro- and
anti-angiogenic factors in favour of the first, released by both tumour and host
cells1-4. Some activators of angiogenesis have been extensively studied like
fibroblast growth factor, vascular endothelial growth factor-b and -c. Examples of
inhibitors of angiogenesis are thrombospondin-1, angiostatin and endostatin4. An
increase in vascularisation also increases the possibility for tumour cells to enter
the circulation and give rise to metastases.  Weidner et al. reported a method to
quantificate angiogenesis. In early breast carcinoma, the density of microvessels
was determined in the primary tumour in areas of most intense revascularisation,
so-called hot spots. It appeared to be a significant prognostic indicator for metas-
tases, relapse free and overall survival5-8. The presence of neovascular hot spots
in axillary lymph node metastases is also associated with a significant reduction
of disease free and overall survival9. 
Surgical resection of a primary tumour may lead to enhanced angiogenesis lead-
ing to accelerated growth of metastases. First of all, elements from normal wound
healing, like fibroblasts, enhance tumour invasiveness and development of
metastases in mouse models10-12.  Also mediators of wound healing, like fibrob-
last growth factor, increase local and distant tumour growth in a melanoma
mouse model13. 
Further, the resection of the primary tumour may lead to growth of its metastases
by changing the balance in angiogenesis factors, with a possible consequence of
loss of inhibitors or rise of activators. An earlier study reported acceleration in
residual tumour growth after resection of a second tumour in mice14-18.
Moreover, reduction of human breast carcinoma and lung carcinoma in a mouse
model was reported after systemic administration of angiostatin or endostatin19,20.
These and more studies suggest a tumour growth related role, which may be
determined by examining tumour related endothelial cells21-23. 
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Occasionally, the phenomenon of accelerated tumour growth after tumour resec-
tion has been described in patients. Resection of bulky non-seminomatous germ-
cell testicular carcinoma was followed by a dramatic relapse24. A similar event
was reported on colorectal liver metastases; an enhancement of vascular density
of the liver metastases was described after removal of the primary tumour25. In
case of renal cell carcinoma, opinions differ: in metastasized renal cell carcino-
ma, regression after nephrectomy is a well known but rare phenomenon26. And a
recent EORTC study shows a better median survival in metastatic renal cell after
immunotherapy in combination with radical nephrectomy compared to
immunotherapy alone27. Thus for different tumour types in model studies and in
humans, an effect of surgery on remaining tumour has been shown. 
The aim of this study was to assess, whether delayed removal of lymph node
metastases after earlier resection of the primary tumour in breast carcinoma
patients would have an effect on angiogenesis in the lymph node metastases. To
this purpose lymph node metastases of patients earlier operated on for primary
breast carcinoma, were compared for MVD and proliferating endothelial cells
with a control, one-stage procedure, group. Further the fraction of proliferating
cells in tumour and metastases was examined.
Patients and methods
Patients
Between January 2000 and July 2001, 222 patients were operated on for breast
carcinoma at a regional teaching hospital. In 33 low suspicion for malignancy
patients, the first procedure was a diagnostic excisional biopsy confirming the
diagnosis breast carcinoma. Afterwards a SLN biopsy was performed. The time
between both operations was recorded. Patient characteristics of the remaining
189 patients and the 33 low suspicion for malignancy patients are collected in
table 1. From 11 of the 33 patients, at least one SLN was tumour positive. In 6 out
of these 11 SLN’s, metastases with a diameter larger than 3 mm were found,
beyond the diameter where angiogenesis becomes essential for further growth1.
Two of these 6 patients were reoperated on because DCIS, but no invasive carci-
noma, was revealed in the resection margins of the excisional biopsy. 
For each of the 6 patients a control patient was sought in the remaining group of
189 patients, who underwent the excision of the primary tumour and SLN biopsy
simultaneously. Patients were matched for age (maximum range 8 years), tumour
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stage, type, grade and positive histopathology of the SLN. A program designed in
MS Excel 2000 for Windows performed the matching procedure. In 5 out of 6
patients the program succeeded in finding at least one matching patient. If more
than one matching patient was available, the patient with the highest tumour load
left in the SLN was chosen as a match. That would leave the highest probability
of tumour in the remaining SLN parts, necessary for additional staining.  
Immunohistochemistry
Of the SLN of these 10 patients, histologic sections were stained in a double indi-
rect sequential immunohistochemical staining procedure as described before28.
First MIB-1 antibody (Neomarkers, USA) was incubated and after peroxidase
labelled on the second layer, stained brown with diaminobenzidine.
Subsequently, the CD 31 antibody (DAKO, Denmark) was incubated and after
alkaline phosphatase labelling on the second layer, stained with new fuchsine.
MIB-1 is a monoclonal antibody directed against the nucleus of endothelial cells,
75
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Primary tumour
                T1
                T2
                Miscellaneous
102 (54%)
69 (36.5%)
18 (9.5%)
30 (90.9 %)
3 (9.1%)
Histologic type
                IDC
                ILC
                Miscellaneous
134 (70.9%)
24 (12.7%)
31 (16.4%)
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5 (15.2%)
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Table 1 Comparison of patient characteristics of the group, who underwent a diagnostic excisional biopsy before the SLN pro-
cedure and the remaining patients (Abbreviations: SLN - sentinel lymph node, IDC - invasive ductal carcinoma, ILC - invasive lob-
ular carcinoma, miscellaneous - intracystic papillary carcinoma/tubular carcinoma/medullary carcinoma/apocrinal carcinoma, n.s. -
not significant, Grade - Nottingham combined histological grade).
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which are at the G2M-phase of cell proliferation. CD31 is a monoclonal antibody
directed against the cytoplasm of endothelial cells. 
Assessment of vascular density and (endothelial) 
proliferating index
Microvessel density (MVD) was quantified according to Weidner in the lymph node
metastases. With low magnification neovascular hot spots were identified. Counts
were made on a 200X field; the result was the highest count at any field at this mag-
nification8. Further, proliferative and non-proliferative endothelial cells in the
lymph node metastatic area were determined by visual counting (figure 1). The
number of MIB1 positive nuclei endothelial cells was divided by the total number
of endothelial cells in the metastatic area and expressed as a percentage, the
endothelial proliferating index. All slides were viewed and quantified by the author
and an experienced pathologist (FT), blinded for patients’ characteristics.
The proliferating index was established by counting the amount of MIB1 positiv-
ity in tumour cell nuclei in primary tumour and SLN metastases.
Statistical analysis
An experienced statistician performed statistical analysis of the data with SPSS
statistical software package for Windows. Significance for patient characteristics
was calculated with Mann Whitney U and chi square test. Univariate analysis of
variance with ANOVA was performed to compare endothelial proliferating index
and MVD of the SLN metastases for all matched pairs. Further the proliferating
index of primary tumour and lymph node metastases were compared.
Results
Of 189 of the 222 patients, resection of the primary tumour and SLNB were per-
formed simultaneously. For the remaining 33 patients, the median period
between the diagnostic excisional biopsy and SLN procedure was 37 days (range
15-100) (figure 2). Patient- and tumour characteristics of the one and two stage
procedure patients were collected in table 1. Note that in the group with delayed
SLNB, the fraction of patients with lower T-stage and smaller tumour size is high-
er than in the group with simultaneous resection. Length of the time interval is
not related to the existence or size of lymph node metastases
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Figure 1 An endothelial cell with a nucleus at the G2M-phase of cell proliferation appears as a cell with red cytoplasm and a
dark brown nucleus as a consequence of the double immunohistochemical staining. Any other cell at the G2M-phase of cell pro-
liferation is pictured as a cell with a dark brown nucleus (MIB-1). Any other endothelial cell not at the G2M-phase is a cell with red
cytoplasm (CD31). The figure contains a proliferating endothelial cell at the arrow, which is occasionally present. 
Magnification: x10 ocular and x40 objective
Figure 2 Histogram of delay between
subsequent operations in breast carcinoma
patients in 2000
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Pathological findings of the five cases and matched controls are presented in
table 2. For these five patients, the median delay between both procedures
amounted to 35 days (range 15-66). The tumour type of all patients consisted of
invasive ductal carcinoma. No statistically significant difference was identified in
the comparison of the endothelial proliferating index between cases and controls
(p=0.31). The MVD seemed to be slightly higher in cases with delayed SLN biop-
sy than in controls, mean and STD, 14.2± 14 and 9.6 ± 10.3, respectively. This dif-
ference was not significant (p=0.65). Similarly, no significant difference was
found in a comparison of the proliferating index of the primary tumour with the
lymph node metastases for both groups of patients (p=0.76).
Discussion
The question, whether resection of the primary tumour in breast carcinoma
patients would lead to increased angiogenesis of the lymph node metastases, is
not affirmed in this study. If an acute effect is taking place, such as in wound heal-
ing, an effect on angiogenesis is likely to be present well within a period of 35
days. Nevertheless, the growth of metastases is a more steady process with in
time increasing functional disturbances. Possibly a mean delay of 35 days is not
78
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Proliferative index
Sentinel lymph node
Age Tumour size (mm) Tumour grade
Primary carcinoma
Epithelial cells Endothelial cells
MVD
Case 1 51 20 1 1% 1% 0/266 1
Control 1 51 15 1 >1% 2% 3/127 9
Case 2 46 15 2 >2% 6.5% 1/408 37
Control 2 42 10 3 35% 12% 0/23 3
Case 3 59 6 2 7.5% 10% 3/462 10
Control 3 56 19 3 5% 25% 2/239 1
Case 4 49 25 3 30% 10% 0/302 18
Control 4 56 24 3 72% 30% 0/232 8
Case 5 73 15 2 3.5% 17.5% 0/25 5
Control 5 77 20 2 15% 5.5% 1/397 27
Cases
Mean(±STD) 56 16 2 8.8 ± 12.1 9.0 ± 6.0 0.0016 ± 0.0012 14.2 ± 14.2
Controls
Mean(±STD) 56 17 2 25.6 ± 29.1 14.9 ± 12.2 0.0073 ± 0.0047 9.6 ± 10.3
Table 2 Patient characteristics of the matched pairs (Abbreviation: MVD=mean vascular density, STD=standard deviation).
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sufficient to detect these differences in metastases. Moreover, no relation is
demonstrated between the length of delay in treatment and size of the lymph
node metastases. Taking these arguments into account, it is likely that the mean
time interval of 35 days seems enough to exclude a major imbalance in angio-
genic factors in the lymph node metastases after resection of the primary tumour.
In this study, the setup is delineated by clinical circumstances. The results might
be distorted by the fact that all primary tumours in these two stage patients were
low suspicion for malignancy at first. Tumour size and stage appeared to be of sig-
nificant better profile in the two-stage group. Therefore patient pairs (one and
two stage procedure) were carefully matched for most significant prognostic fac-
tors (age, tumour type, stage and grade), which should nullify this fact. A mar-
ginally higher MVD was present in the SLN metastasis of patients with delayed
SLN biopsy; this difference was not significant. Moreover, the proliferative frac-
tion of endothelial cells (counted in slides with double immunohistochemical
staining) was low and similar in cases and controls. In addition, in the epithelial
component of the metastases a similar proliferation fraction was found as in the
primary tumour. Although the number of cases is small, an influence of a marked
delay in SLN biopsy on the growth of breast cancer metastases does not seem to
be present.
In mice models an accelerated growth of metastases was found as a consequence
of increased angiogenesis or wound healing mediators after resection of the pri-
mary tumour. However, this has not been supported by this study. Nor was an
increase seen in proliferating index between the primary tumour and lymph node
metastases after resection of the primary tumour, or could any difference in MVD
or endothelial proliferating index be demonstrated between the one and two stage
procedure patients14-18. A high MVD in the SLN is related to a decreased overall
survival. The MVD of both patient groups after excision of the primary tumour was
low. Therefore no diminishment of overall survival of the two stage patients is to
be expected caused by the delay between the subsequent operations9.
If loss of angiogenesis inhibitors would have a significant impact on angiogene-
sis, one would expect to find an increase in mitotic activity of the vascular
endothelial cells and microvessel density, in spite of the small number of
patients17,18. 
No invasive carcinoma was left after the excisional biopsy in any of the patients,
which could have influenced the results, by the production of angiogenic activa-
tors or inhibitors.
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Nowadays, less two or more stage procedures are performed as a consequence of
stereotactic biopsies, the use of ultrasound in axillary staging and techniques to
perform intraoperative examination of the SLN. Also the delay in between subse-
quent operations decreased dramatically. Obviously, delay in between operations
in breast carcinoma patients is to be avoided. If occurring, no significant effect on
angiogenesis was revealed in these patients with these methods. More research
to this interesting subject is warranted.
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Summary & general conclusions
In chapter 1, facts are provided about the lifetime risk for women and mortality
rate of breast cancer in the Netherlands. The most important prognostic factor for
breast cancer survival, axillary lymph node status, is discussed within the light of
the former golden standard for treatment, the axillary lymph node dissection and
its morbidity. A résumé is presented on the development of the sentinel lymph
node (SLN) concept to the present application in breast cancer patients. A
description of the SLN procedure as performed nowadays in most Dutch hospi-
tals, the triple technique, is given. This thesis concentrates on new developments
and consequences of the SLN procedure after the introduction and validation of
the SLN concept. 
The initial experience with a new technique for intraoperative examination of the
SLN at a regional teaching hospital is described in chapter 2. Scrape cytology
appears to be a useful method for intraoperative examination of the SLN. Its accu-
racy, 85%, is comparable with results of imprint cytology and frozen section as
reported in literature. However, as a consequence of a non-uniform distribution
of the metastasis in the SLN and the limited time for intraoperative examination
a higher accuracy seems not feasible. 
In chapter 3, the first results of the SLN procedure performed under local anaes-
thesia are reported, introduced to avoid the disadvantages of the intraoperative
examination of the SLN. The detection rates of the SLNs, ratio of mapped and
revealed SLNs, performed under local and general anaesthesia were compared
and appeared almost identical, respectively 0.99 and 1.0. The learning curve
demonstrated that the procedure under local anaesthesia could quickly be mas-
tered if one is experienced with the performance of SLN biopsies.  The technical
addendum contains a detailed technical description of the SLN procedure under
local anaesthesia.
The results of a hospital-based and literature study on regional recurrence after
a negative SLN biopsy are presented in chapter 4. In contrast to the false nega-
tive rates of the validation studies, the incidence of regional recurrence in current
practice and literature is much lower, respectively 0.46 and 0.25% after a median
follow-up of 26 and 25 months. In a literature review, axillary recurrence
occurred in 8 patients after a median period of 21 months. The natural course of
axillary relapse after a negative SLN biopsy seems to resemble locoregional
recurrence after an ALND. In both groups, about 30% of the patients presented
with synchronous systemic metastases. This percentage rises eventually to 50%,
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in the group of patients with locoregional failure after an ALND. A patient pre-
senting with axillary recurrence should therefore receive therapy conform
locoregional failure, aimed at locoregional and systemic control.
In chapter 5, the accuracy of the MSKCC nomogram was tested on a population
of breast cancer patients in the Netherlands. This nomogram gives an individu-
alised risk estimate for the probability of non-SLN metastases based on eight pre-
dictors.  To this purpose, patient, tumour and SLN metastasis characteristics were
collected of 222 consecutive patients, who underwent a completion ALND. In
spite of the fact that the Dutch and New York patient group differed significantly
with regard to almost all predictive variables, the area under the under the ROC
curve amounted to 0.77, a value very much comparable to the source population.
In consequence, it can be stated that the nomogram provides a reasonably accu-
rate predicted probability for the likelihood of non-SLN metastases in a general
population of breast cancer patients of a regional teaching hospital in the
Netherlands. This suggests that the nomogram’s originally calculated predictive
accuracy may be valid for patient populations that differ considerably from the
population in whom it was developed. Its result can support both doctor and
patient in the choice whether or not an ALND is desirable in individualised cir-
cumstances.
In chapter 6 the accuracy of surgical oncologists in predicting the likelihood for
non-SLN metastases compared with the MSKCC nomogram was assessed.
Further the influence of the nomogram results on clinical decision making was
examined. The concordance-index between clinical estimates and actuarial like-
lihood amounted to 0.78, indicating moderate concurrence. The intersurgeon
variation, however, was important. About 25% of the surgeons was influenced by
nomogram information and decided in one or more patients to abandon the
cALND. The type of hospital nor the amount of experience influenced predicting
abilities or the clinical decision making process. Therefore individual predictions
of surgical oncologists for non-SLN metastases do not correlate well with the
MSKCC nomogram. The distribution between intersurgeon predictions for one
scenario is important. The nomogram is superior to clinical estimations for pre-
dicting the likelihood for non-SLN metastases.
In the final study, presented in chapter 7, the question is addressed, whether
delayed SLNB after earlier resection of the primary tumour in breast cancer
patients would lead to increased angiogenesis in the lymph node metastases.
Though the median delay for SLN biopsy in the two-stage procedure group
amounted to 35 days, no statistically significant difference was identified in the
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comparison of the endothelial proliferating index and MVD (mean vascular den-
sity) between the matched pairs of patients. Also no significant difference was
found in a comparison of the proliferating index of the primary tumour with the
lymph node metastases for both groups of patients. Further no relation is
revealed between the length of delay and existence or size of the lymph node
metastases. Therefore these data cannot objectify an increase of angiogenesis or
tumour proliferation of the lymph node metastases after resection of the primary
tumour. Since a high MVD is related to decreased overall survival, this might sug-
gest that survival was not influenced by the delay between both procedures.  
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Samenvatting & algemene conclusies
De inleiding, hoofdstuk 1, geeft informatie over de kans die een vrouw heeft
gedurende haar leven borstkanker te ontwikkelen en het meest recente sterfte-
cijfer van deze ziekte in Nederland. De belangrijkste prognostische factor, de
okselklierstatus, wordt besproken alsmede de voormalige “gouden standaard”
behandeling, de okselklierdissectie (OKD) en de mogelijke morbiditeit daarna.
Er wordt een samenvatting gegeven van de ontwikkeling van het schildwacht-
klierconcept tot en met de hedendaagse toepassing ervan bij mammacarcinoom-
patiënten. De schildwachtklierbiopsie (SWKB), zoals nu in de meeste Nederlandse
ziekenhuizen toegepast, wordt beschreven. Dit proefschrift  handelt over nieuwe
ontwikkelingen en gevolgen van de SWKB na de introductie en validatie van het
SWK-concept.
In hoofdstuk 2 worden de eerste ervaringen met een nieuwe techniek voor intra-
operatief onderzoek van de SWK beschreven. Schraapcytologie blijkt een bruikba-
re methode voor intraoperatief onderzoek. De nauwkeurigheid van deze methode,
85%, is vergelijkbaar met de resultaten van depcytologie en vriescoupeonderzoek,
zoals gerapporteerd in de literatuur. Een hogere nauwkeurigheid lijkt niet haal-
baar als gevolg van een ongelijkmatige verdeling van metastasen in de SWK en de
beperkte tijd die beschikbaar is voor intraoperatief onderzoek.
De bovengenoemde nadelen van intraoperatief onderzoek hebben geleid tot de
introductie van de SWKB onder lokale anesthesie. Hoofdstuk 3 rapporteert de
eerste resultaten van deze techniek.  De ratio van afgebeelde en ontdekte SWK’s,
uitgevoerd onder lokale en algehele anesthesie, werd onderzocht en bleek ver-
gelijkbaar (namelijk 0,99 en 1,0). De leercurve laat zien dat de procedure snel te
leren is, als men de techniek onder algehele anesthesie beheerst. Het technisch
addendum bevat een beschrijving van de techniek van de SWKB onder lokale
anesthesie.
De resultaten van een ziekenhuis- en literatuurstudie naar de prevalentie van
een regionaal recidief na een SWKB zonder metastase worden gepresenteerd in
hoofdstuk 4. Het lage aantal regionale recidieven dat in de praktijk wordt gevon-
den en in de literatuur worden gemeld, te weten 0,46 en 0,25% na een mediane
follow-up van 26 en 25 maanden, komt niet overeen met het aantal fout negatie-
ve SWKB uit de eerder uitgevoerde validatiestudies. Een recidief in de oksel trad
op bij een totaal van 8 patiënten in de literatuur en praktijk na een mediane
periode van 21 maanden na een negatieve SWKB. Het natuurlijk beloop van
patiënten met een regionaal recidief na een negatieve SWKB lijkt dat van een
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regionaal recidief na een OKD te weerspiegelen. In beide groepen presenteert
ongeveer 30% van de patiënten zich met synchrone afstandsmetastasen. Dit per-
centage stijgt uiteindelijk tot 50% in de groep met een regionaal recidief na een
OKD. Dientengevolge zou de behandeling van patiënten met een regionaal reci-
dief na een negatieve SWKB vergelijkbaar moeten zijn met die van patiënten met
een regionaal recidief na een OKD, zowel gericht op locoregionale als systemi-
sche controle. 
In hoofdstuk 5 wordt de betrouwbaarheid van het Memorial Sloan-Kettering
Cancer Center-nomogram getest op een populatie van Nederlandse mammacar-
cinoompatiënten. Het nomogram, dat is gebaseerd op 8 prognostische factoren,
verschaft een individuele risicoschatting van de kans op positieve okselklieren na
een positieve SWKB. Van 222 Nederlandse patiënten, die na een positieve SWKB
een OKD ondergingen, werden patiënt-,  tumor- en SWK-karakteristieken verza-
meld. Ondanks het feit dat de Nederlandse en Amerikaanse patiëntenpopulatie
met betrekking tot vrijwel alle prognostische factoren significant verschilden,
bedroeg de “area under the curve” 0,77. Dit getal is vergelijkbaar met de  oor-
spronkelijke Amerikaanse waarde. Dientengevolge kan men stellen dat het
nomogram een redelijk voorspellende waarde heeft voor de kans op positieve
okselklieren na een positieve SWKB voor een algemene populatie van mam-
macarcinoompatiënten van een perifeer opleidingsziekenhuis in Nederland. De
uitkomsten suggereren dat het nomogram van toepassing kan zijn op populaties
die significant verschillen van de oorspronkelijke Amerikaanse groep patiënten.
De nomogram uitkomsten kunnen zowel arts als patiënt ondersteunen bij de
beslissing, of een OKD al dan niet wenselijk is in bepaalde omstandigheden.
In hoofdstuk 6, wordt de nauwkeurigheid van de risicoschatting op positieve
okselklieren na een positieve SWKB van chirurgen die dagelijks patiënten met
borstkanker behandelen vergeleken met het MSKCC nomogram. Tevens wordt
de invloed van nomogramresultaten op klinische besluitvorming onderzocht. De
concordantie-index tussen de klinische schattingen en de nomogramuitkomsten
bedroeg 0,78, hetgeen duidt op matige overeenstemming. De variatie tussen de
schattingen van de individuele chirurg-oncologen was groot. Ongeveer 25% van
de chirurg-oncologen lijkt beïnvloed te worden door het nomogramresultaat en
besluit bij één of meer patiënten geen OKD uit te voeren. Het soort ziekenhuis of
de ervaring van een chirurg-oncoloog heeft geen invloed op zijn of haar vermo-
gen tot risicoschatten of het proces van klinische besluitvorming.
Individuele risicoschattingen van chirurg-oncologen komen dus maar matig
overeen met de resultaten van het MSKCC nomogram en de spreiding tussen de
individuele risicoschattingen voor een scenario blijken groot. Dientengevolge is
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het nomogram superieur aan klinische risicoschatting van de kans op positieve
okselklieren na een positieve SWKB.
De laatste studie in hoofdstuk 7 poogt de vraag te beantwoorden of een verlate
SWKB na een voorafgaande excisie van de primaire mammatumor, een toename
van angiogenese in de lymfekliermetastase tot gevolg heeft. Alhoewel de media-
ne vertraging tussen excisie van de primaire tumor en de SWKB 35 dagen
bedroeg, werd er geen significant verschil waargenomen bij vergelijking van de
endotheelproliferatieindex en gemiddelde vasculaire dichtheid van de SWK met
gematchte patiënten, die beide procedures op 1 dag ondergingen. Ook werd er
geen significant verschil gevonden bij vergelijking van de proliferatieindex van
de primaire tumor met de lymfekliermetastase van beide patiëntengroepen. Er
bestaat ook geen relatie tussen de duur van de periode tussen excisie van de pri-
maire tumor en SWKB en het aanwezig zijn van dan wel de grootte van de lym-
fekliermetastase.
Deze data kunnen derhalve geen toename van angiogenese of tumorproliferatie
van de lymfekliermetastase objectiveren na eerdere excisie van de primaire
tumor. Omdat een hogere gemiddelde vasculaire dichtheid gerelateerd wordt aan
een afname van de overleving, suggereert deze studie dat de overleving niet
nadelig wordt beïnvloed door de vertraging tussen beide procedures.
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Abstract
A sentinel lymph node (SLN) biopsy in breast cancer patients, performed under
local anaesthesia (LA), has advantages such as a more efficient use of operating
room and pathologist’s time. Additionally, it provides a histologic diagnosis prior
to definitive breast surgery. This prevents a decision based on possibly equivocal
results of intraoperative examination of the SLN and provides the patient with
more specific information. The aim of this report is to present the technical and
organisational aspects of a SLN biopsy under local anaesthesia.
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Introduction
The sentinel lymph node procedure is a reliable technique for axillary staging in
patients with clinical T1-2N0 breast cancer1. In most hospitals, the SLN biopsy is
combined with the definitive breast surgery. The sentinel lymph node (SLN) is
than often examined intraoperatively. If metastatic disease is revealed, an axillary
lymph node dissection can be performed in the same session2-6. 
However, this operational sequence has several drawbacks. No single intraoper-
ative technique –frozen section, touch prep or scrape cytology- reveals all
metastatic disease. False-negatives lead to reoperation in 11-26% of all patients
with negative intraoperative examination results7-11. The use of intraoperative
techniques also puts the pathologist under time pressure to present a diagnosis12-
14. Another disadvantage is the time spent waiting for the results, which prolongs
the duration of general anaesthesia and the use of the operating room12-17.
Perhaps the most compelling reason for questioning intraoperative examination
of the SLN is the fact that patients enter the operation without knowing the exact
diagnosis and the course of the subsequent operation13,15,16.
In order to deal with the drawbacks mentioned above, a method was developed
to perform a SLN procedure under local anaesthesia in breast cancer
patients12,14,17-20. An earlier study by Smidt et al. already examined and proved
feasibility21. The aim of this report is to present the technical and organisational
aspects of this method as currently performed in our clinics.
Patients and methods
Organisational aspects
Patients with a suspicious breast laesion referred from the breast cancer screen-
ing program or by a general physician, are seen by a surgical oncologist and spe-
cialised nurse at the breast cancer clinics of both hospitals. Diagnostic imaging
and ultrasound guided tumour cytology take place immediately. If unequivocal,
the results can be presented to the patient the same day.
If a breast laesion is proven to be malignant, unifocal and clinically T1-2N0, the
SLN biopsy is planned. The appointments with the nuclear physician for injection
of the radioactive tracer and the static lymphoscintigraphy are scheduled. The
outpatient operation room is booked for the SLN procedure performed under
local anaesthesia and the patient is provided with a non-steroidal antiflogistic
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drug to take, as a pre-emptive analgesia, 4 hours before the SLN biopsy and the
day after. 
The clinical operation room is booked one week later for definitive breast
surgery. Outpatient clinic appointments are scheduled to discuss the histologic
diagnosis and subsequent adjuvant treatment. 
The sentinel lymph node imaging
The nuclear physician injects the afternoon before surgery the radioactive trac-
er. As a tracer, 60 MBq of technetium-99m nanocolloid is used, which is injected
periareolar in the diseased breast quadrant22. A static lymphoscintigraphy is per-
formed at the morning of the day of the procedure. The nuclear physician reviews
the images and marks the location of the primary SLN on the skin. If no SLN is
visualised, additional tracer (30mBq) will be injected. If even then no SLN can be
identified with a static lymphoscintigraphy, the nuclear physician will consult the
surgeon. Depending on the patient and pathology the procedure will be contin-
ued with blue dye only. 
The sentinel lymph node biopsy
The SLN procedure under local anaesthesia is performed in the outpatient oper-
ating room. A surgical oncologist and a scrub nurse perform the operation.
Another nurse chats informally with the patient during the entire procedure.
Background music is chosen in consultation with the patient. The surgical nurs-
es of the outpatient clinic received special training on the subject and equipment.
No premedication or intravenous analgesia is administered. Thus, patients are
allowed to eat and drink before and immediately after the operation. 
A peripheral venous access is established in order to allow a quick response to
possible allergic reactions to the blue dye23,24. Before desinfecting and draping, 1
ml blue dye (Bleu patente V; Guerbet, Aulnay-sous-Bois, France) diluted with 1 ml
lidocaine 0.5% is injected into the tissue surrounding the tumour or biopsy cavi-
ty. The lymphatic drainage of the blue dye is then stimulated by massage during
three min. The patient is now positioned with the arm at a 90-degree abduction
angle or holding the hand behind the head. The nuclear physician already
marked the location of the SLN on the skin. The incision is a line from the ante-
rior to the dorsal axillary line, immediately caudal to the axillary hair line, with
an average length of 4 cm, somewhat adjusted to the marking of the nuclear
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physician. Local anaesthesia is given by subcutaneous infiltration of 10 ml lido-
caine 0.5% with adrenaline 1:200.000. As the procedure advances, additional lido-
caine -average 5 to 10 ml-  is injected on demand. The amount of locally used
anaesthesia remains always far below the recommended safe dose25. 
After the skin incision cautery can be useful to provide adequate hemostasis.
Further on, the adrenaline induces vasoconstriction. The axillary fascia is
entered by scissors dissection. The wound edges are held by Langenbeck retrac-
tors. The fatty tissue is now sharp and blunt dissected until a blue vessel, the
preferable guide to the SLN, is visible. If none is encountered during dissection to
the thoracic wall, the gamma probe (Neoprobe, Johnson&Johnson Medical,
Hamburg, Germany) serves as a guide. Harvesting of the node is performed with
scissors and haemoclips. Hemostasis is carefully controlled and the skin is closed
with intracutaneous Monocryl 4-0. Patients can leave the hospital within 15 min
after the biopsy.
The duration of the procedure depends on the habitus of the patient, the experi-
ence of the surgeon, the number of SLNs shown on the lymphoscintigraphy and
the amount of nuclear uptake. On average the procedure lasts 25 min and the
length of the skin incision is four cm21. 
Histologic examination
The SLN is bisected and both halves are embedded in paraffin. Each halve is step-
sectioned at 500-micrometer intervals at three levels and stained with both
haematoxylin and eosin, and immunohistochemical staining (Cam5.2). 
Discussion
Only few authors have reported on sentinel lymph node biopsy under local anaes-
thesia in patients with breast cancer12,14,17,21. All refer to some or all of the advan-
tages mentioned previously. This study reflects the elaborated concept of the SLN
biopsy under local anaesthesia based cumulative experience of two breast cancer
centres.
In our opinion, the most important advantage is the fact that patients are informed 
about the histologic diagnosis of the sentinel lymph nodes before the definitive
breast surgery. This knowledge might change the mind of a patient concerning
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the definitive breast surgery (mastectomy vs. breast-conserving) and, as a conse-
quence, patient satisfaction concerning that decision may increase. One can also
spare the patients the distress of consenting to an axillary lymph node dissection,
which ultimately proves to be unnecessary16.
A minor drawback is the additional operation, for under general anaesthesia at
least 60% of the breast cancer patients is operated on only once. Further a nurse
has to pay full attention to the patient, especially in anxious patients. She/he can
also pass the need for additional anaesthesia.
Considerable variety exists among authors in the practice of administration of
sedation and intravenous analgesia. To our experience both are unnecessary, if
one provides sufficient analgesia and a nurse who can make the patient feel at
ease12,14,17,21. 
The radioactive tracer was injected in the subareolar plexus. This injection mode
yields a higher success rate of identifying SLNs while less extra-axillary nodes are
imaged as compared with peritumoral injection22. The discussion on the value of
extra-axillary nodes is still ongoing. These nodes seem to have only minor clini-
cal consequences for a small number of patients26-28.
No difficulties were met during introduction of the SLN under local anaesthesia
with respect to organisational and technical aspects. To our opinion the main
change is the possibility to present the patient with the definitive histopathologic
results of the SLN instead of the equivocal results of intraoperative examination.
As a consequence, it creates the chance to inform a patient more specifically and
the patient is better able to make a well thought decision concerning the defini-
tive breast and axillary surgery. 
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met je eigen laatste loodjes.  • Deborah, Caroline en Bob, dank voor jullie hulp
bij het invoeren van data. Deborah wil ik apart bedanken voor de samenwerking
die leidde tot het nomogram artikel.  • Carla Wauters: de samenwerking met de
afdeling pathologie leverde het eerste artikel op. Bedankt voor je adviezen ten
aanzien van de tekst en de prachtige foto's.  • Erik Thunnissen wil ik bedanken
voor de samenwerking aangaande het angiogenese artikel.  • Charles van Berlo:
het idee van SLN onder lokale verdoving kwam van jou. Bedankt voor je inspi-
ratie.  • De Henny C. Dirven stichting wil ik bedanken voor het in 2004 aan mij
toekennen van hun borstkankeronderzoeksaanmoedigingsprijs! Het was een
extra stimulans dit proefschrift tot een goed einde te brengen.
Mijn vrienden en (schoon-)familieleden wil ik bedanken voor hun interesse,
maar nog veel meer voor de gezelligheid en afleiding. Speciaal dank aan Lideke
en Annekien, dat jullie me op deze speciale dag terzijde willen staan. En aan
Sandra en Laura: als zussen zijn we hechter geworden en dat voelt goed.
Lieve Truus en Tonnie, pap en mam, als piepjonge ouder kan ik jullie nog meer
waarderen. Jullie hebben me altijd alle vrijheid gegeven mijn eigen keuzes te
maken. Met (onder andere) dit als resultaat. Bedankt dat jullie er gewoon altijd
zijn!
Lieve Linde, je komst heeft een extra dimensie aan mijn/ons leven gegeven. Bij
je geboorte dacht ik nog dat ‘houden van’ in afstand uit te drukken was. Inmiddels
weet ik beter...
100
Dankwoord
bw.schmidt  05-12-2005  14:23  Pagina 100
Allerliefste Ivo, je humor en relativeringsvermogen waren onontbeerlijk de afge-
lopen periode. Wat hebben we het goed samen... LZ&VM 
En nu: ‘laten we dansen, mijn liefste’.
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Curriculum vitae
Marjolein Smidt werd op 19 april 1972 in Geleen geboren. Zij bracht haar jeugd
door in Hulsberg. In 1984 ging zij naar het gymnasium van het Bernardinus-
college te Heerlen, waar zij in 1990 eindexamen deed. Datzelfde jaar begon zij
met de studie Geneeskunde aan de Universiteit Maastricht. Daar had zij een
actief studentenleven, met als hoogtepunt het voorzitterschap van de organisatie
van de algemene eerstejaars introductie, de Inkom. Later volgde zij diverse
chirugisch georiënteerde co-schappen over de grens, onder andere in het
Krankenhaus der Stadt Kitzbühel, het Diakonis Krankenhaus in Salzburg,
Oostenrijk en het Moi University Teaching Hospital te Eldoret, Kenia. In septem-
ber 1997 haalde zij haar artsexamen met genoegen.
Na haar artsexamen werkte zij als AGNIO van november 1997 tot augustus 1998
op de afdeling Heelkunde van het Amphia Ziekenhuis, lokatie Langendijk, te
Breda. Van augustus 1998 tot december 1999 werkte zij als AGNIO op de afdeling
Heelkunde van het Canisius-Wilhelmina Ziekenhuis te Nijmegen (opleider: dr.
E.D.M. Bruggink). Daar begon zij de opleiding tot chirurg in januari 2000. In deze
periode werd de basis gelegd voor dit proefschrift onder leiding van dr. L.J.A.
Strobbe. De opleiding werd vervolgd in het Universitair Medisch Centrum St
Radboud te Nijmegen, met als opleider prof.dr. R.P. Bleichrodt. In oktober 2004
ontving zij de Henny C. Dirven prijs voor patiëntgericht schildwachtklieronder-
zoek bij mammacarcinoompatiënten. De opleiding werd afgesloten met een dif-
ferentiatiejaar chirurgische oncologie onder leiding van dr. W.B. Barendregt
(opleider) en dr. L.J.A. Strobbe (opleider chirurgische oncologie) wederom in het
Canisius-Wilhelmina Ziekenhuis te Nijmegen.
Marjolein woont samen met Ivo Panhuizen. Zij werden in augustus 2005 de
gelukkige ouders van een wolk van een dochter, Linde.
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